Document:

exv10w15

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

Exhibit 10.15

CROSS LICENSE AGREEMENT

     This Cross License Agreement (“Cross License”), dated as of September 1, 2005 (“Effective
Date”), is made by and between Intuitive Surgical, Inc., a Delaware corporation having its
principal place of business at 950 Kifer Road, Sunnyvale, California 94086, (“ISI”), and Hansen
Medical, Inc., a Delaware corporation having its principal place of business at 380 North Bernardo
Avenue, Mountain View, California 94043 (“Hansen”). Hansen and ISI may be referred to herein
individually as a “Party”, and collectively as the “Parties”.

RECITALS

     WHEREAS, ISI and Hansen each owns or controls rights under various patents, utility models and
applications therefor in various countries of the world with respect to the medical devices
industry; and

     WHEREAS, each Party desires to acquire licenses under such patents, utility models and
applications therefor of the other Party and to grant licenses under such patents and utility
models and applications therefor to the other Party, all for specific purposes and as provided in
and subject to the terms of this Cross License.

     NOW, THEREFORE, in consideration of the mutual covenants and premises contained herein, the
Parties agree as follows:

     1. DEFINITIONS

     As used in this Cross License, the following capitalized terms shall have the following
meanings:

          1.1 “Acquisition” means (A) any consolidation or merger of a Party with or into any
other corporation or other entity or person, or any other corporate reorganization, other than any
such consolidation, merger or reorganization in which the stockholders of a Party immediately prior
to such consolidation, merger or reorganization, continue to hold at least a majority of the voting
power of the surviving entity in substantially the same proportions (or, if the surviving
entity is a wholly owned subsidiary, its parent) immediately after
such consolidation, merger
or reorganization; or (B) any transaction or series of related transactions to which a Party is a
party in which in excess of fifty percent (50%) of such Party’s voting power is transferred;
provided that an Acquisition shall not include any transaction or series of transactions
principally for bona fide equity financing purposes in which cash is received by such Party or any
successor or indebtedness of such Party is cancelled or converted or a combination thereof.

          1.2 “Affiliate” means, with respect to a Party, any entity that controls, is
under

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

1

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

common control with, or is controlled by, such Party. For the purposes of this definition, the
term “control” (with correlative meanings for the terms “controlled by” and “under common control
with”) means that the applicable entity: (a) has beneficial ownership of greater than fifty percent
(50%) of the voting securities of the subject corporation or other business organization with
voting securities, (b) has greater than a fifty percent (50%) interest in the net assets or profits
of the subject partnership or other business organization without voting securities, or (c) has the
actual ability (through contract or otherwise) to direct and control the management and general
business activities of the subject corporation, partnership or other business organization.

          1.3 “Applicable Law” means, as to any Person, any statute, law, rule, regulation,
directive, treaty, judgment, order, decree or injunction of any Governmental Authority that is
applicable to or binding upon such Person or any of its properties.

          1.4 “Asset Transfer” shall mean a sale, lease, exclusive license or other disposition
of all or substantially all of the assets of a Party.

          1.5 “CIP” means a continuation-in-part patent application as defined in Section 201.08
of the Manual of Patent Examining Procedures.

          1.6 “Co-exclusive” means, with respect to the grant of license rights in a specified
field of use and under identified intellectual property owned or controlled by the licensor, (a)
that such license is the sole license under such intellectual property in such field of use, (b)
that the licensor covenants that it and its Affiliates shall not grant to any other entity or
party, any license or similar rights in such field of use under such licensor intellectual property
(or any part thereof), including any license under such intellectual property to make, have made,
use, offer for sale, sell, distribute and import products within the specified field of use (but
provided that the foregoing shall not prevent licensor from granting (or impliedly granting) such
rights solely to customers of licensor products that are covered by the applicable patent rights
and solely to the extent required for such customers to use, re-sell, export and/or import such
products), and (c) that the licensor retains the rights to use and practice such intellectual
property in such field of use for its own account (i.e., despite the grant to the licensee, the
licensor is not prevented from making, having made, using, marketing, offering for sale, selling,
importing, distributing (directly or indirectly) or otherwise exploiting its products or services
in the specified field of use under such intellectual property.)

          1.7 “Effective Date” shall have the meaning set forth in the Preamble of this Cross
License.

          1.8 “Governmental Authority” means any domestic or foreign government, governmental
authority, court, tribunal, agency or other regulatory, administrative or judicial agency,
commission or organization, and any subdivision, branch or department of any of the foregoing.

          1.9 “Hansen Disposable” has the meaning set forth in Section 3.3(b).

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

2

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

          1.10 “Hansen Field of Use” means the research, development, manufacture, use, sale,
promotion, distribution and importation of medical devices and systems for intravascular approaches
for the diagnosis and/or treatment of cardiovascular, neurovascular and peripheral vascular
diseases.

          1.11 “Hansen Know-How” means the information disclosed to ISI by Hansen prior to the
Effective Date, but excluding all information disclosed in the Hansen Patents.

          1.12 “Hansen Investors Rights Agreement” shall have the meaning set forth in Section
3.2.

          1.13 “Hansen Patent” means: (a) any patent or patent application that has a filing
date on or prior to the Effective Date and that is either (i) owned by Hansen or an Affiliate of
Hansen, or (ii) licensed to Hansen or an Affiliate of Hansen, with the right to grant sublicenses
under such patents and patent applications; (b) any divisional, continuation, or
continuation-in-part (but only to the extent of claims in such CIP that are based on and enabled by
the subject matter disclosed in a patent or patent application meeting the criteria of subclause
(a) above) application that is based upon the patents or patent applications in subclause (a)
above, and all foreign patent applications claiming priority from any of the foregoing patents and
patent applications; and (c) any patent issuing on any of the foregoing applications, and including
any reissue, re-examination, renewal, extension, or supplementary protection certificate (or the
like) of any such patent. Notwithstanding the foregoing, if a patent or patent application that
would otherwise qualify as a Hansen Patent under this Section 1.13 is subject to an agreement
between Hansen (or a Hansen Affiliate) and a third party requiring Hansen (or a Hansen Affiliate)
to pay a royalty, net sales payment, or other consideration to such third party as a result of the
practice of the licensed rights, then such patent or patent application shall be included in the
Hansen Patents only if ISI agrees to bear the cost of such royalty, net sales payment, or other
consideration that Hansen (or a Hansen Affiliate) is obligated to pay under such agreement based on
ISI’s use or practice of such patent rights. For clarity, the term “Hansen Patent” shall not
include any patent or application (x) that is owned or controlled by an entity that is not an
Affiliate of Hansen as of the Effective Date and that subsequently becomes an Affiliate of Hansen;
or (y) rights to which Hansen acquires from a third party after the Effective Date, whether by
merger, acquisition, asset purchase, license or otherwise.

          1.14 “Hansen Royalty Product” means either a Hansen System Product or a Hansen
Disposable.

          1.15 “Hansen System Product” has the meaning set forth in Section 3.3(a).

          1.16 “Hansen Trade Secret” means any particular, identifiable Hansen Know-How that is
and remains, at the applicable time, an actual trade secret of Hansen, but excluding any Hansen
Know-How that is retained in the unaided memory of an ISI employee.

          1.17 “Insolvent Party” has the meaning set forth in Section 5.3.

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

3

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

          1.18 “ISI Field of Use” means (a) the research, development, manufacture, use, sale,
promotion, distribution and importation of medical devices and systems for use in endoscopic,
laparoscopic, thoracoscopic or open diagnosis and/or surgical procedures, including, without
limitation, urologic surgery, ENT surgery, gynecologic surgery, general surgery, thoracic and
cardiovascular surgery; and (b) the research, development, manufacture, use, sale, promotion,
distribution and importation of medical devices and systems for gastrointestinal, respiratory, ENT,
urologic and gynecologic endoluminal diagnosis and/or surgery. For clarity, the research,
development, manufacture, use, sale, promotion, distribution and importation of medical devices and
systems for intravascular approaches for the diagnosis and/or treatment of cardiovascular,
neurovascular and peripheral vascular diseases are expressly excluded from the “ISI Field of Use”.

          1.19 “ISI Know-How” means the information disclosed to Hansen by ISI prior to the
Effective Date (including without limitation information retained in the unaided memory of [*],
obtained during their prior employment by ISI), but excluding all information disclosed in the ISI
Patents.

          1.20 “ISI Licensed Product” means a product or service manufactured or sold by ISI
that embodies, falls within the scope of, or is made using a method described in, any Valid Claim
of a Hansen Patent.

          1.21 “ISI Patent” means: (a) any patent or patent application that has a filing date
on or prior to the Effective Date, is either (i) owned by ISI or an Affiliate of ISI, or (ii)
licensed to ISI or an Affiliate of ISI, with the right to grant sublicenses under such patents and
patent applications; (b) any divisional, continuation, or continuation-in-part (but only to the
extent of claims in such CIP that are based on and enabled by the subject matter disclosed in a
patent or patent application meeting the criteria of subclause (a) above) application that is based
upon the patents or patent applications in subclause (a) above, and all foreign patent applications
claiming priority from any of the foregoing patents and patent applications; and (c) any patent
issuing on any of the foregoing applications, and including any reissue, re-examination, renewal,
extension, or supplementary protection certificate (or the like) of any such patent.
Notwithstanding the foregoing, if a patent or patent application that would otherwise qualify as an
ISI Patent under this Section 1.18 is subject to an agreement between ISI (or an ISI Affiliate) and
a third party requiring ISI (or an ISI Affiliate) to pay a royalty, net sales payment, or other
consideration to such third party as a result of the practice of the licensed rights, then such
patent or patent application shall be included in the ISI Patents only if Hansen agrees to bear the
cost of such royalty, net sales payment, or other consideration that ISI (or an ISI Affiliate) is
obligated to pay under such agreement based on Hansen’s use or practice of such patent rights. For
clarity, the term “ISI Patent” shall not include any patent or application (x) that is owned or
controlled by an entity that is not an Affiliate of ISI as of the Effective Date and that
subsequently becomes an Affiliate of ISI; or (y) rights to which ISI acquires from a third party
after the Effective Date, whether by merger, acquisition, asset purchase, license or otherwise.

          1.22 “ISI Trade Secret” means any particular, identifiable ISI Know-How that is and
remains, at the applicable time, an actual trade secret of ISI, but excluding any ISI Know-

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

4

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

How that is retained in the unaided memory of a Hansen employee.

          1.23 “Materials Cost” means the sum of the following amounts paid by Hansen to a third
party, all of which shall be calculated in accordance with U.S. generally accepted accounting
principles consistently applied:

               (a) raw materials and packaging materials for producing the Hansen Products,

               (b) manufacturing, packaging, and/or sterilizing Hansen Products or any component thereof, and

               (c) with respect to the foregoing, all taxes (other than income taxes) and customs duty
charges imposed by governmental authorities with respect thereto, to the extent paid by Supplier
and not reimbursed or refunded by a third party.

          1.24 “Net Sales,” with respect to a Hansen Royalty Product, means the actual amounts
invoiced by Hansen or its distribution Affiliates to its respective customers or non-Affiliate
distributors (excluding internal sales or transfers to Hansen’s distribution Affiliates that
further distribute the product) on the sale or other commercial disposition of such Hansen Royalty
Product (and including any amounts of installation charges that are in excess of normal and
customary installation charges for similar products), less the sum of the following deductions: (a)
discounts, returns, promotional allowances, volume and incentive rebates, chargebacks, retroactive
price reductions and other similar adjustments or allowances actually given to such customers in
the normal course of business; (b) sales or use taxes, excise taxes, value-added taxes, and
customs duties and other governmental charges included in the invoiced amount; and (c) normal and
customary outbound transportation, shipping, and insurance, prepaid or allowed, if separately
itemized on the invoice to the customer, all of the foregoing accounted for under U.S. Generally
Accepted Accounting Principles as included in Hansen’s audited financial statement. Notwithstanding
the foregoing, in the case of disposition of the product to an Affiliate of Hansen (excluding
internal sales or transfers to Hansen’s distribution Affiliates that further distribute such
product), Net Sales will be the sales price of such product generally available to an unaffiliated
third party in an arms length transaction making similar quantity commitments at similar times.

          1.25 “Person” means a natural individual, Governmental Authority, partnership, firm,
corporation or other entity.

          1.26 “Valid Claim” means a claim of an issued or granted unexpired patent, which claim
has not been declared invalid or unenforceable by an un reversed decision or judgment of a court of
competent jurisdiction or other appropriate governmental authority from which no further appeal can
be taken, and which claim has not been admitted to be invalid through disclaimer, or found to be
unenforceable or no longer patentable through reissue, reexamination, interference, or opposition.

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

5

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

          1.27 “Year” shall mean each twelve (12) month period beginning on the Effective Date
and thereafter on the anniversary date thereof.

          1.28 “Share Transfer Agreement” has the meaning set forth in Section 3.1.

          1.29 “Term” has the meaning set forth in Section 5.1.

     2. GRANT OF LICENSES

          2.1 Cross Licenses.

               (a) From ISI to Hansen. Subject to the terms and conditions of this Cross License, ISI hereby
grants to Hansen a Co-exclusive, worldwide, perpetual (except as provided in Article 5 herein),
royalty-bearing, and non-assignable (except as provided in Section 9.1 herein) license under the
ISI Patents to use and practice all inventions claimed therein solely in the Hansen Field of Use,
including to make, have made, use, promote, offer for sale, import and sell Hansen Royalty Products
in the Hansen Field of Use. Hansen will have the right to sublicense such rights solely in
accordance with Section 2.4.

               (b) From Hansen to ISI. Subject to the terms and conditions of this Cross License, Hansen
hereby grants to ISI a Co-exclusive, worldwide, perpetual (except as provided in Article 5 herein),
fully paid and royalty-free (except as provided in Section 1.11 herein), and non-assignable (except
as provided in Section 9.1 herein) license under the Hansen Patents to use and practice all
inventions claimed therein solely in the ISI Field of Use, including to make, have made, use,
promote, offer for sale, import and sell ISI Licensed Products solely in the ISI Field of Use. ISI
will have the right to sublicense such rights solely in accordance with Section 2.4.

          2.2 Know-How License From ISI to Hansen. Subject to the terms and conditions of this
Cross License, ISI hereby grants to Hansen a non-exclusive, worldwide, perpetual (except as
provided in Article 5 herein), fully-paid, royalty-free, and non-assignable (except as provided in
Section 9.1 herein) license (a) to use and practice all the ISI Know-How (including ISI Trade
Secrets (if any)) solely in connection with the research, development, manufacture, promotion, use,
import and sale of Hansen products in the Hansen Field of Use, and (b) to use and practice any ISI
Know-How that are not ISI Trade Secrets in connection with the research, development, manufacture,
promotion, use, import and sale of Hansen products outside the Hansen Field of Use. Hansen shall
have the right to sublicense such rights solely to customers of Hansen products solely in
connection with the sale and use of such products, and to collaborators of Hansen assisting in
developing Hansen products in the Hansen Field of Use provided such collaborators have a need to
know such ISI Know-How for the purposes of such collaboration and who execute a confidentiality
agreement with terms at least as protective as the terms of Section 6.5.

          2.3 Know-How License From Hansen to ISI. Subject to the terms and conditions of this
Cross License, Hansen hereby grants to ISI a non-exclusive, worldwide,

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

6

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

perpetual (except as provided in Article 5 herein), fully-paid, royalty-free, and
non-assignable (except as provided in Section 9.1 herein) license (a) to use and practice all the
Hansen Know-How (including Hansen Trade Secrets (if any)) solely in connection with the research,
development, manufacture, promotion, use, import and sale of ISI products in the ISI Field of Use,
and (b) to use and practice any Hansen Know-How that are not Hansen Trade Secrets in connection
with the research, development, manufacture, promotion, use, import and sale of ISI products
outside the ISI Field of Use. ISI shall have the right to sublicense such rights solely to
customers of ISI products solely in connection with the sale and use of such products, and to
collaborators of ISI assisting in developing ISI products in the ISI Field of Use provided such
collaborators have a need to know such Hansen Know-How for the purposes of such collaboration and
who execute a confidentiality agreement with terms at least as protective as the terms of Section
6.5.

          2.4 Sublicensing. Neither Party may sublicense any of the rights and licenses granted
to it under Section 2.1 to any third party without the prior written consent of the other party.
Either Party may request the other Party’s consent to grant it the right to sublicense the rights
and licenses granted in Section 2.1 to such Party’s partners with whom such Party is involved in
joint product development, and the Party receiving such request will reasonably consider it and
will not unreasonably withhold such consent. Notwithstanding any of the foregoing, ISI’s consent
shall not be required for Hansen to sublicense any of the rights and licenses granted to it under
Section 2.1 solely to customers of Hansen products that are covered by the applicable patent rights
and solely to the extent required for such customers to use, re-sell, export and/or import such
products, and Hansen’s consent shall not be required for ISI to sublicense any of the rights and
licenses granted to it under Section 2.1 solely to customers of ISI products that are covered by
the applicable patent rights and solely to the extent required for such customers to use, re-sell,
export and/or import such products.

          2.5 Retained Rights. For clarity, none of the licenses granted in Sections 2.1 through
2.4 shall restrict (a) Hansen from itself using and practicing all inventions claimed in the Hansen
Patents in any field of use and (b) ISI from itself using and practicing all inventions claimed in
the ISI Patents in any field of use.

          2.6 Disclosure of Patent Files. Each Party shall, to the extent such disclosure has
not already been made, provide to the other Party within [*] days after the Effective Date complete
and accurate copies of all unpublished patent applications as filed owned or licensed by such Party
as of the Effective Date. Further, each Party shall respond accurately to reasonably requests by
the other Party to provide updates as to the status of the prosecution of applications in the ISI
Patents or Hansen Patents (as applicable) and to provide copies of any newly filed applications in
the ISI Patents or Hansen Patents (as applicable).

          2.7 Compliance with Sublicense Obligations. Hansen covenants that it shall comply with
any applicable terms of any license agreement between ISI and a third party that grant to ISI
license rights under the third party’s patents, which patents are ISI Patents that sublicensed to
Hansen under the terms of this Cross License. ISI covenants that it shall comply with any
applicable terms of any license agreement between Hansen and a third party that grant

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

7

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

to Hansen license rights under the third party’s patents, which patents are Hansen Patents
that sublicensed to ISI under the terms of this Cross License.

     3. CONSIDERATION

          3.1 Stock Transfer. In consideration of the rights and licenses granted by ISI to
Hansen under this Cross License, Hansen will issue to ISI Five Hundred Thousand (500,000) shares of
Hansen’s Series B Preferred Stock pursuant to and in accordance with the terms of the Share
Transfer Agreement entered into by the Parties, the form of which is set forth in Exhibit A.

          3.2 Investor Rights. ISI shall within five (5) business days after the Effective Date,
enter into an Amended and Restated Investor Rights Agreement among Hansen, ISI and the other
preferred stockholders of Hansen (the “Hansen Investor Rights Agreement”) in substantially the form
attached as Exhibit B.

          3.3 Royalty. In consideration of the rights and licenses granted by ISI to Hansen
under Section 2.1(a) of this Cross License, Hansen shall pay ISI:

               (a) Royalties of [*] of the Net Sales of all Hansen hardware products (including proprietary
Hansen software components) comprising imaging, guidance or catheter control systems for use in the
Hansen Field of Use (collectively, “Hansen System Products”) during the Term; and

               (b) Royalties, at a royalty rate of ranging from [*] to [*] on the Net Sales of all [*] used
in the Hansen Field of Use [*], including, without limitation, [*]

                    (i) [*]

                    (ii) [*]

                    (iii) [*]; or

                    (iv) [*]

               (c) The Parties hereby acknowledge and agree that the foregoing method of calculating
royalties due under this Cross License shall apply to all Hansen Royalty Products as specified in
this Section 3.3, without regard to whether such any such Hansen Royalty Product embodies or
practices any of the claims of the ISI Patents. The Parties further agree that this method of
calculating royalties is more convenient for the Parties than attempting to resolve the question of
whether each particular Hansen Royalty Product sold does, or does not, embody or practice any claim
of the ISI Patents.

          3.4 Minimum Royalties. Hansen will pay ISI yearly license minimum royalties as
follows:

                    (a) [*]

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

8

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

                    (b) [*]

     The minimum royalty payments are nonrefundable, but they are creditable against royalty
payments due pursuant to Section 3.3 until the entire credit is exhausted. The [*] minimum
royalties will be paid in equal [*] installments.

     4. ACCOUNTING AND REPORTS

          4.1 Payments and Royalty Reports. Hansen shall make royalty payments to ISI in
accordance with Section 3 above on a quarterly basis. Within [*] days after the end of each
calendar quarter during the Term, after commercial sales of Hansen Royalty Products has commenced,
Hansen shall deliver to ISI a written report setting forth the total number of units of the Hansen
Royalty Products sold or otherwise commercially disposed (or, if appropriate, indicating that no
Hansen Royalty Product was sold during such calendar quarter) and a calculation of the royalties
owed to ISI hereunder for the applicable quarterly period. If no royalties are due hereunder in any
calendar quarter, Hansen shall so indicate in its written report. Hansen shall accompany such
written report with an appropriate payment of royalty due for such quarterly period.

          4.2 Overdue Payments. If payment of any amount due to ISI becomes overdue, ISI may,
without prejudice to its other rights or remedies, charge interest on a day to day basis from the
due date until the payment has been paid in full, at the rate of one percent (1.0%) per month or,
if less, such other rate as may be the maximum permitted by law. Hansen shall not be entitled to
withhold payment in whole or in part on the grounds that it has a claim, counterclaim or set off
against ISI.

          4.3 Taxes. Hansen shall be permitted to deduct from payments made by Hansen to ISI
under this Cross License any foreign or domestic governmental taxes or charges of any kind that
Hansen may be required by law to withhold from such payments. Hansen shall use commercially
reasonable efforts to minimize any such taxes or charges. Hansen shall provide ISI with official
receipts issued by the appropriate taxing authority, or such other evidence as is reasonably
requested by ISI to establish that such taxes or charges have been paid. If, on the other hand, ISI
has the legal obligation to collect such taxes, then ISI alone shall be responsible for paying such
amount.

          4.4 Books And Records; Audit. Hansen will keep complete and accurate books and records
showing the information by which Hansen arrived at a royalty determination and shall, during the
Term and for a period of three (3) years after termination of this Cross License, permit a mutually
agreed auditor from a nationally recognized firm to inspect and copy said records as such auditor
may deem necessary to complete the inspection (but not to exceed one (1) inspection per year and no
more than one (1) inspection of records covering any particular time period) solely to verify the
accuracy of Hansen’s royalty reports. Such inspection may be made by ISI hereunder at any time and
from time to time during regular business hours upon at least five (5) business days’ advance
written notice. The fees and expenses of such inspection shall be borne by ISI, except that, if an
underpayment in royalties of more than five

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

9

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

percent (5%) of the total royalties due to ISI hereunder for any payment period is discovered,
then such fees and expenses shall be borne by Hansen. If ISI agrees to pay a Hansen licensor
royalty or other amounts for the sublicense to ISI of Hansen Patents that are licensed to Hansen,
then the above records and audit provisions will apply to ISI mutatis mutandis as to ISI products
covered by such Hansen Patents.

     5. TERM AND TERMINATION

          5.1 Term. This Cross License shall commence on the Effective Date and shall continue
in effect until the expiration of the last to expire of the ISI Patents and the Hansen Patents,
(“Term”), unless earlier terminated in accordance with the following provisions of this Section 5.
Upon such expiration, the license rights granted in Sections 2.3 and 2.4 shall survive.

          5.2 Material Breach.

               (a) If either Party believes that the other Party is in material breach of this Agreement,
then such Party may deliver notice of such alleged breach to the other Party. In such written
notice, the noticing Party shall identify the actions or conduct that such Party would consider to
be an acceptable cure of such breach. The Party receiving such notice shall use diligent efforts to
cure such breach as soon as practicable after receiving such written notice to cure such breach,
unless such Party believes that it is not in breach, in which case the Parties shall meet promptly
thereafter and discuss in good faith the issue and seek to reach a resolution mutually acceptable
to both Parties. If the allegedly breaching Party fails to cure such noticed breach, then, except
as otherwise provided in subsection (b) or in Section 5.3 below, the noticing Party shall not be
permitted to terminate this Agreement (and each Party covenants and agrees that the Party shall not
seek, in any court or other proceeding, to terminate the Agreement as a remedy except as permitted
in subsection (b) or Section 5.3 below), but may seek and obtain all other remedies as are
available to such Party at law or in equity pursuant to Section 5.7 below, if such breach is proved
to have occurred and not have been cured.

               (b) If Hansen breaches its obligation to pay royalties as required in Section 3.3, or to pay
royalties to a licensor of ISI as contemplated in Section 1.18 for patent rights sublicensed to
ISI, then ISI may deliver notice of such breach to Hansen, specifying the amount that is owed and
the basis for ISI’s belief that such amounts are owed and past-due. If ISI breaches its obligation
to pay royalties to a licensor of Hansen as contemplated in Section 1.13 for patent rights
sublicensed to ISI, then Hansen may deliver notice of such breach to ISI, specifying the amount
that is owed and the basis for Hansen’s belief that such amounts are owed and past-due. If Hansen
or ISI disputes that such amount is actually owed, such dispute shall be resolved (a) by the
auditor selected pursuant to Section 4.4, if such dispute is solely as to the amount of royalties
owed, and not as to whether there is a royalty obligation for particular products at issue, or (b)
by litigation in court in accordance with Section 9.3. The following sentence shall not apply
unless and until such dispute is resolved in the non-breaching Party’s favor, and the breaching
Party does not pay the amount determined to be owed within [*] days of such determination. If the
breaching Party’s failure to pay when due royalty amounts owed that are in excess of [*], and such
Party does not cure such failure to pay the owed royalties by the

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

10

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

date [*] days after such notice, then such breach will be deemed to be a “Material Breach,”
for which the non-breaching Party may terminate this Agreement within 30 days by written notice to
the Party in breach, provided if such dispute is resolved in litigation in court, such termination
will be effective at such time no appeal is or can be taken from the court’s decision.

          5.3 Infringement Outside Licensed Field; Termination for Willful Infringement.

               (a) Each Party acknowledges and agrees that the license rights granted under this Agreement to
it by the other Party are limited to the specific, identified fields of use. Hansen covenants that
it shall not knowingly practice any issued ISI Patents outside of the Hansen Field of Use in a
manner that infringes the ISI Patents, and ISI covenants that it shall not knowingly practice any
issued Hansen Patents outside the ISI Field of Use in a manner that infringes the Hansen Patents.

               (b) If ISI believes that Hansen is violating its covenant in subsection (a) above and is
infringing the ISI Patents by actions outside the Hansen Field of Use, ISI may give Hansen notice
of such belief (the “Belief of Infringement”), which notice shall include all details that are the
basis for such belief and ISI’s proposal to cure such violation, and the Parties shall then meet
promptly thereafter under Section 5.7(a) to discuss the noticed Belief of Infringement and ISI’s
proposed resolution and to seek to reach a resolution of such Dispute. If Hansen does not cease the
violation that is the basis for such Belief of Infringement within [*] days of the date Hansen
receives such notice, and if the Parties do not reach a mutually acceptable other resolution to
such matter within [*] days after the receipt of the notice, then either Party may have the matters
relating to the Dispute and claim arising out of this Section 5.3(b) settled by litigation in court
in accordance with Section 9.3, to determine if Hansen in fact has infringed one or more valid and
enforceable issued ISI Patents outside the Hansen Field of Use. For the avoidance of doubt, Hansen
may raise as affirmative defenses to any infringement action brought by ISI, or as a basis for
declaratory relief action brought by Hansen, any and all defenses, available at law or equity, that
are available in patent actions. If such litigation results in a judgment of infringement from
which no appeal can be or is taken, and Hansen, despite such infringement judgment by the court,
fails to cease conducting the actions that were determined by the court to be infringing the ISI
Patents by the date [*] days after the date after which no appeal can be or is taken (the
“Determination Date”), then such failure shall be a “Material Breach,” for which ISI may terminate
this Agreement within 30 days by written notice to Hansen.

               (c) If Hansen believes that ISI is violating its covenant in subsection (a) above and is
infringing the Hansen Patents by actions outside the ISI Field of Use, Hansen may give ISI notice
of such belief (the “Belief of Infringement”), which notice shall include all details that are the
basis for such belief and Hansen’s proposal to cure such violation, and the Parties shall then meet
promptly thereafter under Section 5.7(a) to discuss the noticed Belief of Infringement and Hansen’s
proposed resolution and to seek to reach a resolution of such Dispute. If ISI does not cease the
violation that is the basis for such Belief of Infringement within [*] days of the date ISI
receives such notice, and if the Parties do not reach a mutually acceptable other

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

11

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

resolution to such matter within [*] days after the receipt of the notice, then either Party
may have the matters relating to the Dispute and claim arising out of this Section 5.3(c) settled
by litigation in court in accordance with Section 9.3, to determine if ISI in fact has infringed
one or more valid and enforceable issued Hansen Patents outside the ISI Field of Use. For the
avoidance of doubt, ISI may raise as affirmative defenses to any infringement action brought by
Hansen, or as a basis for declaratory relief action brought by ISI, any and all defenses, available
at law or equity, that are available in patent actions. If such litigation results in a judgment of
infringement from which no appeal can be or is taken, and ISI, despite such infringement judgment
by the court, fails to cease conducting the actions that were determined by the court to be
infringing the Hansen Patents by the date [*] days after the Determination Date (as to such
judgment), then such failure shall be a “Material Breach,” for which Hansen may terminate this
Agreement within 30 days by written notice to ISI.

          5.4 Termination for Bankruptcy.

               (a) Notice of Bankruptcy Event. If either of the following events (a “Bankruptcy
Event”) occurs with respect to a Party (the “Bankrupt Party”), such Insolvent Party shall
immediately notify the other Party of the occurrence of such event:

                    (i) Any application, petition or action for relief is submitted by such Bankrupt Party for
commencement of proceedings under bankruptcy, corporate reorganization, insolvency or moratorium
law or any other law for the relief of, or relating to, debtors, now or hereafter in effect, or
makes any assignment for the benefit of creditors covering all or substantially all of its assets;
or

                    (ii) An involuntary petition is filed against such Bankrupt Party under any bankruptcy statute
now or hereafter in effect, or a custodian, receiver, trustee, assignee for the benefit of
creditors (or other similar official) is appointed to take possession, custody or control of any
property of such Insolvent Party.

               (b) Right to Terminate. If the Bankruptcy Event is not cured or otherwise terminated
within 90 days following occurrence the Bankruptcy Event, the Party that is not the Bankrupt Party
shall have the right to terminate this Cross License by giving notice in writing to the Bankrupt
Party.

          5.5 Effect of Termination. In the event of termination of this Cross License by one
Party (“Terminating Party”) pursuant to Section 5.2 or 5.3 or 5.8 or paragraph 7 of Exhibit C, all
licenses and rights granted hereunder by the Terminating Party to the other Party (“Terminated
Party”), shall automatically terminate as of the date of such termination of this Cross License
(except as otherwise provided in Section 5.8), but the licenses and rights granted hereunder by the
Terminated Party to the Terminating Party shall survive such termination, subject to the terms and
conditions of this Cross License. In the event of termination of this Cross License by one Party
pursuant to Section 5.4, all licenses and rights granted hereunder by the each Party to the other
Party shall automatically terminate as of the date of such termination of this Cross License.
Termination or expiration of the Cross License shall not relieve any Party

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

12

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

of any obligation or liability accrued under this Cross License prior to termination or
expiration.

          5.6 Survival. Upon the expiration or any termination of this Cross License, the
provisions of Sections 1, 2.2, 2.3, 4, 5.5, 5.6, 6.4, 6.5, 7.1, 7.2, 8 and 9 all shall survive such
expiration or termination.

          5.7 Dispute Resolution.

               (a) If any dispute or issue arises between the Parties (a “Dispute”), including any alleged
breach of the terms or obligations of a Party (such as an allegation of breach of the covenants
under Section 5.3(a)), or the extent of a Party’s rights under the terms hereof, then the Parties
shall resolve such Dispute pursuant to the terms of this Section 5.7. As to any such Dispute,
either Party may give notice to the other Party to seek to resolve such Dispute. Within ten days of
giving of any such notice, the CEOs of the Parties shall meet to discuss the Dispute and seek to
reach a mutually agreeable resolution to the Dispute, which resolution shall be set forth in
writing signed by the Parties. If the CEOs of the Parties cannot reach agreement on a resolution to
the Dispute that is subject of a notice provided under this Section 5.7(a), within [*] days of
commencing discussions to resolve the matter, then either Party may have such Dispute resolved by
litigation in a court of applicable jurisdiction (subject to Section 9.3) except as provided in
Section 5.7(b), and provided further that the remedies available to the Parties in such litigation
are expressly limited by the applicable terms of this Agreement (including Section 5.2(a)).

               (b) A Party shall have the rights to initiate, on written notice to the other Party, the
procedure set forth in Exhibit C at any time, for the Parties to discuss a particular new product
being developed by such Party that is intended to be commercialized outside such Party’s licensed
field (i.e., outside the Hansen Field of Use as to a Hansen new product, or outside the ISI Field
of Use as to an ISI new product) to determine if such new product would, if sold in such intended
use, infringe any valid and enforceable issued patent in the other Party’s patent portfolio. Upon
such notice, the parties shall proceed under the terms of Exhibit C. For any dispute under Exhibit
C that is to be resolved by arbitration, such dispute shall be heard and a resolution determined by
an arbitration conducted in San Francisco, California under the American Arbitration Association
Commercial Arbitration Rules and Supplementary Procedures for Large Complex Disputes (together the
“AAA Rules”) by three arbitrators who are neutral and independent of the Parties and who have
expertise in the medical device field and in patents relating to medical devices. Each Party shall
select an arbitrator, and the selected arbitrators will select a third arbitrator, provided that
each such selected arbitrator must meet the foregoing criteria to be empowered to serve in the
arbitration. If the arbitrators selected by the Parties cannot agree on a third arbitrator within
thirty (30) days, the third arbitrator will be selected by the AAA. The arbitration shall be
conducted in accordance with the AAA Rules, as such rules and procedures are supplemented or
modified by the terms of this Section 5.7 and/or by written agreement of the Parties. The Parties
shall have such discovery rights as is reasonable in the case and as the arbitrators may allow,
consistent with the goal of providing for a full and fair hearing of the Dispute and an equitable
resolution of the Dispute, but in no event broader than that discovery permitted under the Federal
Rules of Civil Procedure. In conducting the arbitration,

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

13

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

the arbitrators shall apply the California Rules of Evidence and shall allow raising of all
affirmative defenses to an infringement action, available at law or in equity, in their analysis of
whether a valid and enforceable issued patent is infringed. The arbitrators will hear each Party’s
case and positions as to the Dispute. In any event, such remedies cannot be contrary to the terms
of Exhibit C, and the arbitrators cannot award any Party any punitive, special, indirect or
consequential damages. The Parties will keep the arbitration and the results of the arbitration
confidential.

               (c) Notwithstanding any other provision of this Section 5.7, each Party shall be entitled to
seek a preliminary injunction or other temporary equitable remedy in court to protect such Party
from immediate, imminent harm by breach of this Agreement by the other Party. Each Party
acknowledges and agrees that the other Party hereto would be irreparably damaged in the event of a
continuing breach of Section 5.3(a).

          5.8 Termination by Hansen. Twelve and one-half (12.5) years after the Effective Date,
Hansen shall have the right to terminate the Cross License and all its obligations under Section
3.3 by written notice to ISI. Upon such termination, all licenses granted by ISI to Hansen shall
terminate, except that the license granted under Section 2.2 shall survive such termination
indefinitely solely as to ISI Know-How that are not ISI Trade Secrets, and all licenses granted by
Hansen to ISI under Section 2.1(b) and 2.3 shall survive such termination, subject to all other
applicable terms of the Cross License.

     6. MUTUAL COVENANTS

          6.1 No Solicitation. Each Party agrees that it will not, directly or indirectly,
solicit, recruit, retain, hire or employ any person that such Party knows, or has reason to know,
is employed by the other Party. Notwithstanding the foregoing, nothing herein shall be construed to
prohibit either Party from placing advertisements for employment that are directed at the public at
large in any newspaper, trade magazine, journals or other periodical in general circulation.

          6.2 Third Party Infringement.

               (a) ISI Patents. If a Party becomes aware that any ISI Patent is infringed by a third
party in the Hansen Field of Use (a “Hansen Field Infringement”), such Party shall promptly notify
the other Party in writing, which notice shall set forth the facts known to such Party regarding
such believed infringement in reasonable detail. ISI shall have the primary right, but not the
obligation, to institute, prosecute, and control any action or proceeding with respect to
infringement of ISI Patents Rights, by counsel of its own choice, and, if such action or proceeding
is brought by ISI, Hansen shall have the right, at its own expense, to be represented in such
action or proceeding by counsel of its own choice, and also to join such action as a plaintiff to
assert claims for infringement if such Hansen Field Infringement has resulted in lost profits by
Hansen or its Affiliates due to lost sales. For any infringement of the ISI Patents outside of the
Hansen Field of Use, ISI shall have the sole and exclusive rights to take action regarding such
infringement, including enforcing the patents and settling any such actions. Notwithstanding the
foregoing, if ISI does not bring such action or proceedings as to such

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

14

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

Hansen Field Infringement within a period of one hundred twenty (120) days after receiving
notice from Hansen, Hansen shall have the right to bring and control (except as otherwise provided
below) any such action by counsel of Hansen’s own choice (a “Hansen Action”), [*]. For the purpose
of this Section 6.2(a), [*] shall require that [*], the following factors, which the parties agree
are [*], reasonably and in good faith: [*]. For any Hansen Action, ISI has the right with counsel
of its own choice, to defend itself against, and to control the responses to, any claim or defense
or counterclaim raised in the Hansen Action against ISI or regarding the validity or enforceability
of any ISI Patents.. The Parties will reasonably cooperate in the prosecution and defense of claims
concerning the defendant.

               (b) Hansen Patents. If a Party becomes aware that any Hansen Patent is infringed by a
third party in the ISI Field of Use (an “ISI Field Infringement”), such Party shall promptly notify
the other Party in writing, which notice shall set forth the facts known to such Party regarding
such believed infringement in reasonable detail. Hansen shall have the primary right, but not the
obligation, to institute, prosecute, and control any action or proceeding with respect to such ISI
Field Infringement of Hansen Patents Rights, by counsel of its own choice, and, if Hansen brings
such action or proceeding, ISI shall have the right, at its own expense, to be represented in such
action or proceeding by counsel of its own choice, and also to join such action as a plaintiff to
assert claims for infringement if such ISI Field Infringement has resulted in lost profits by ISI
or its Affiliates due to lost sales. With respect to any ISI Field Infringement that is causing a
material, detrimental impact on ISI, Hansen agrees to meet with ISI to discuss such infringement in
good faith and to reasonably consider ISI’s requests regarding Hansen taking action to cause the
cessation of such infringement. Notwithstanding the foregoing, if Hansen does not bring such action
or proceedings as to such ISI Field Infringement within a period of one hundred twenty (120) days
after receiving notice from ISI, ISI shall have the right to bring and control (except as provided
below) any such action by counsel of ISI’s own choice (an “ISI Action”), [*]. For the purpose of
this Section 6.2(b), [*] shall require that [*], the following factors, which the parties agree are
[*], reasonably and in good faith: [*]. For any ISI Action, Hansen has the right with counsel of
its own choice, to defend itself against, and to control the responses to, any claim or defense or
counterclaim raised in the ISI Action against Hansen or regarding the validity or enforceability of
any Hansen Patents.. The Parties will reasonably cooperate in the prosecution and defense of claims
concerning the defendant.

               (c) Cooperation. If one Party brings any action or proceeding as provided above, the
other Party agrees, if necessary, to give the first Party reasonable assistance to file and to
prosecute such suit, at the filing Party’s expense.

               (d) Allocation of Recoveries. The costs and expenses of all suits brought by either
Party under this Section 6.2 shall be reimbursed on a pro-rata basis to both Parties out of any
damages or other monetary awards recovered in such actions in favor of either Hansen and/or ISI.
Any amounts of such damages or other monetary awards recovered in such actions remaining after such
reimbursement shall be paid first to each Party according to the amounts of damages awarded to the
Party for lost sales as proved by the Party in such action (on a pro rata basis based on the
amounts of lost sales damages awarded to each Party, if applicable), and any remaining amounts of
such damages or other awards to then be divided

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

15

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

between Hansen and ISI with [*] of the remainder to the Party bringing and prosecuting such
action or proceeding, and [*] to the other Party. No settlement or consent judgment or other
voluntary final disposition of a suit under this Section 6.2 may be entered into without the joint
consent of Hansen and ISI (which consent shall not be withheld unreasonably).

          6.3 Patent Marking. Hansen agrees to use reasonable efforts to mark to the extent
required by applicable law, statutes and regulations relating to patent marking all products that
Hansen is aware are claimed by claims of the ISI Patents (or the labels or packaging therefor) that
are made, used, imported, sold or distributed by or on behalf of Hansen and its distributors. ISI
agrees to use reasonable efforts to mark to the extent required by applicable law, statutes and
regulations relating to patent marking all products that ISI is aware are claimed by claims of the
Hansen Patents (or the labels or packaging therefor) that are made, used, imported, sold or
distributed by or on behalf of ISI and its distributors.

          6.4 Indemnification.

               (a) By Hansen. Hansen shall indemnify, defend and hold harmless ISI and its employees,
officers, directors and agents (each, an “ISI Indemnified Party”) from and against any and all
liability, loss, damage, cost, and expense (including reasonable attorneys’ fees) to any Third
Party (collectively, a “Liability”) which the ISI Indemnified Party may incur, suffer or be
required to pay resulting from any suit, action, claim or proceeding brought by the Third Party
based on or arising out of: (i) the breach by Hansen of any representation, warranty, covenant or
obligation contained in this Cross License, or (ii) the manufacture, promotion, sale or use of any
product by Hansen or its licensee (other than ISI). Notwithstanding the foregoing, Hansen shall
have no obligation under this Cross License to indemnify, defend or hold harmless any ISI
Indemnified Party with respect to any Liabilities or claims, demands, costs or judgments to the
extent that they result from: (1) the willful misconduct or negligent acts or omissions of ISI or
any of their respective employees, officers, directors or agents, or (2) the manufacture,
promotion, sale or use of any product by ISI or its licensee (other than Hansen).

               (b) By ISI. ISI shall indemnify, defend and hold harmless Hansen and its employees,
officers, directors and agents (each, a “Hansen Indemnified Party”) from and against any and all
liability, loss, damage, cost, and expense (including reasonable attorneys’ fees) to any Third
Party (collectively, a “Liability”) which the Hansen Indemnified Party may incur, suffer or be
required to pay resulting from any suit, action, claim or proceeding brought by the Third Party
based on or arising out of: (i) the breach by ISI of any representation, warranty, covenant or
obligation contained in this Cross License, or (ii) the manufacture, promotion, sale or use of any
product by ISI or its licensee (other than Hansen). Notwithstanding the foregoing, ISI shall have
no obligation under this Cross License to indemnify, defend or hold harmless any Hansen Indemnified
Party with respect to any Liabilities or claims, demands, costs or judgments to the extent that
they result from: (1) willful misconduct or negligent acts or omissions of Hansen, or any of its
employees, officers, directors or agents, or (2) the manufacture, promotion, sale or use of any
product by Hansen or its licensee (other than ISI).

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

16

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

               (c) Procedures. The obligations of the indemnifying Party under Sections 6.4(a) and
(b) are conditioned upon the delivery of written notice to the indemnifying Party of any potential
Liability promptly after the indemnified party becomes aware of such potential Liability. The
indemnifying Party shall have the right to assume the defense of any suit or claim related to the
Liability if it has assumed responsibility for the suit or claim in writing; however, if in the
reasonable judgment of the indemnified party, such suit or claim involves an issue or matter which
could have a materially adverse effect on the business operations or assets of the indemnified
Party, the indemnified Party may waive its rights to indemnity under this Cross License and control
the defense or settlement thereof, but in no event shall any such waiver be construed as a waiver
of any indemnification rights such Party may have at law or in equity. If the indemnifying Party
defends the suit or claim, the indemnified Party may participate in (but not control) the defense
thereof at its sole cost and expense. Neither Party may settle a claim or action related to a
Liability without the consent of the other Party, if such settlement would impose any monetary
obligation on the other Party or require the other Party to submit to an injunction or otherwise
limit the other Party’s rights under this Cross License. Any payment made by a Party to settle any
such claim or action shall be at its own cost and expense.

          6.5 Confidentiality.

               (a) The Parties recognize that, in connection with the performance of this Cross License, each
Party (in such capacity, the “Disclosing Party”) may disclose “Confidential Information” (as
defined below) to the other Party (the “Receiving Party”). For purposes of this Cross License,
"Confidential Information” means proprietary or confidential information (whether owned by the
Disclosing Party or a third party to whom the Disclosing Party owes a non-disclosure obligation)
regarding the Disclosing Party’s business or technology that is disclosed to the Receiving Party
and is marked as confidential at the time of disclosure to the Receiving Party, or if disclosed in
oral form, is identified as confidential at the time of oral disclosure and reduced in writing or
other tangible (including electronic) form including a prominent confidentiality notice and
delivered to the Receiving Party within thirty (30) days of disclosure. “Confidential Information”
shall not include the Cross License, the terms and conditions thereof and the transactions
contemplated hereby and thereby (which information shall be governed by Section 6.6 of this Cross
License) and information that the Receiving Party can demonstrate:

                    (i) was known to the Receiving Party free of any obligation of confidence at the time of the
disclosure by the Disclosing Party;

                    (ii) has become publicly known through no wrongful act of the Receiving Party;

                    (iii) has rightfully been received by the Receiving Party from a third party;

                    (iv) was communicated by the Disclosing Party to an unaffiliated third party free of any
obligation of confidence; or

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

17

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

                    (v) has been independently developed by the Receiving Party without use or reference to any
Confidential Information of the Disclosing Party.

               (b) The Receiving Party agrees (x) not to use any such Confidential Information other than as
permitted under this Cross License (y) not to disclose any such Confidential Information, except
(1) to its employees who are reasonably required to have the Confidential Information in connection
herewith or with any of the other Transaction Documents, (2) to its agents, representatives,
attorneys and other advisers that have a need to know such Confidential Information, (3) pursuant
to, and to the extent of, a request or order by a Governmental Authority, or (4) or to the extent
such disclosure is reasonably necessary in filing or prosecuting patent, copyright and trademark
applications, prosecuting or defending litigation, complying with applicable governmental
regulations, obtaining regulatory approvals, marketing Products, or otherwise required by law;
provided, however, that if a Receiving Party is required by law or regulation to
make any such disclosure of a Disclosing Party’s Confidential Information it will give reasonable
advance notice to the Disclosing Party of such disclosure requirement and, except to the extent
inappropriate in the case of patent applications, will use its reasonable efforts to secure
confidential treatment of such Confidential Information required to be disclosed. The Receiving
Party agrees to take all reasonable measures to protect the secrecy and confidentiality of, and
avoid disclosure or unauthorized use of, the Disclosing Party’s Confidential Information.

               (c) Each Party acknowledges and agrees that (i) its obligations under this Section 6.5
are necessary and reasonable to protect the other Party and its business, and (ii) any violation of
these provisions could cause irreparable injury to the other Party for which money damages would be
inadequate, and (iii) as a result the other Party shall be entitled to obtain injunctive relief
against the threatened or pending breach of the provisions of this Section 6.5 without the
necessity of proving actual damages. The Parties agree that the remedies set forth in this
Section 6.5 are in addition to and in no way preclude any other remedies or actions that
may be available at law or under this Cross License.

          6.6 Confidentiality of Cross License; Publicity.

               (a) Each Party agrees that the existence of the Cross License, the terms and conditions
thereof and the transactions contemplated hereby and thereby shall be treated as confidential
information and that no reference thereto shall be made without the prior written consent of the
other Party (which consent shall not be unreasonably withheld or delayed) except (a) as required by
Applicable Law including, without limitation, by the SEC and the rules and regulations of any
applicable securities exchange or automated quotation system, or to the extent such disclosure is
reasonably necessary in prosecuting or defending litigation; provided, however,
that if a Party is required by law or regulation to make any such disclosure of such information it
will give reasonable advance notice to the other Party of such disclosure requirement and will use
its reasonable efforts to secure confidential treatment of such information required to be
disclosed, (b) to such Party’s accountants, attorneys and other professional advisers, banks,
existing or potential financing sources, including to potential investors, provided that
such Persons undertake in writing (or are otherwise bound by rules of

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

18

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

professional conduct) to keep such information strictly confidential, (c) in connection with
the enforcement of this Cross License, (d) in connection with an actual or proposed Acquisition or
Asset Transfer of a Party or the acquisition or proposed acquisition of stock or assets by a Party
of any third party or the merger with or into any third party whether or not such transaction
constitutes an Acquisition, provided that such Persons undertake in writing to keep such
information strictly confidential (e) to a potential transferee of all or part of such Party’s
Securities in a Transfer made in accordance with this Cross License, provided that such
transferee undertakes in writing to keep such information strictly confidential, or (f) pursuant to
a press release approved by the other Party.

               (b) The Parties will consult with each other, in advance, with regard to the terms of all
proposed press releases, public announcements and other public statements with respect to the
transactions contemplated hereby. Any Party intending to disclose the terms of this Cross License
shall provide the nondisclosing Party an opportunity to review and comment on the intended
disclosure in reasonably sufficient time (such time period to depend on the urgency of the intended
disclosure) prior to public release, and shall provide the other Party with a written copy thereof,
in order to allow such other Party to comment upon such disclosure; provided however, such notice
and opportunity to review shall not be required for a disclosure which is substantially in a form
previously approved where the underlying facts disclosed in that previously approved disclosure are
still true, and where the circumstances surrounding the disclosure have not changed.

               (c) With respect to complying with the disclosure requirements of the SEC or any securities
exchange or automated quotation system in connection with any required filing of this Cross
License, the filing Party shall seek confidential treatment of this Cross License from the SEC or
securities exchange or automated quotation system and shall provide the other Party with at least
forty-eight (48) hours to review and comment on any such proposed filing. The filing Party shall
use reasonable efforts to incorporate the non-filing Party’s comments to such confidential
treatment request.

     7. WARRANTIES; DISCLAIMERS.

          7.1 No Warranty. Nothing contained in this Cross License shall be construed as:

               (a) a warranty or representation by either Party as to the validity, enforceability or scope
of any Hansen Patents or ISI Patents;

               (b) an agreement by either Party to bring or prosecute actions or suits against third parties
for infringement, or conferring any right to the other Party to bring or prosecute actions or suits
against third parties for infringement. It is specifically agreed between the Parties that the
existence of such alleged infringement by any third party, if any, shall not be a ground for the
refusal to make or a ground for the request for the reduction of the payments to be made by Hansen
under this Cross License;

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

19

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

               (c) conferring any right to either Party to use in advertising, publicity, or otherwise, any
trademark, trade name or names of the other Party, or any contraction, abbreviation or simulation
thereof;

               (d) conferring on either Party, by implication, estoppel or otherwise, any licenses or other
rights under any patent, copyright, trade secrets or trademarks of the other Party, except the
licenses and rights expressly granted hereunder;

               (e) an obligation of a Party to furnish to the other Party any technical information or
know-how, including ISI Know-How or Hansen Know-How;

               (f) a warranty or representation that the exercise of any of the rights granted under this
Cross License will be free from infringement of or will not violate any intellectual property
rights or other proprietary rights of any third party; or

               (g) an obligation on either Party to prosecute, maintain or obtain any patents or utility
models or applications therefor.

          7.2 WARRANTY DISCLAIMER. EXCEPT AS EXPRESSLY PROVIDED IN SECTION 7.3, NEITHER PARTY
MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND WITH RESPECT TO, AND HEREBY EXPRESSLY DISCLAIMS
ALL OTHER WARRANTIES AS TO, THE PATENTS OR KNOW-HOW SUCH PARTY LICENSES TO THE OTHER PARTY UNDER
THIS CROSS LICENSE OR ANY OTHER SUBJECT MATTER OF THIS CROSS LICENSE. BOTH PARTIES SPECIFICALLY
DISCLAIM ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND
NONINFRINGEMENT WITH RESPECT TO THE ISI PATENTS, THE HANSEN PATENTS OR ANY OTHER SUBJECT MATTER OF
THIS CROSS LICENSE.

          7.3 Limited Warranties.

               (a) Each Party represents and warrants to the other Party that: (i) it is duly organized and
validly existing under the laws of its jurisdiction of incorporation or formation, and has full
corporate or other power and authority to enter into this Cross License and to carry out the
provisions hereof; (ii) it is duly authorized to execute and deliver this Cross License and to
perform its obligations hereunder, and the person or persons executing this Cross License on its
behalf has been duly authorized to do so by all requisite corporate or partnership action; and
(iii) this Cross License is legally binding upon it, enforceable in accordance with its terms, and
does not conflict with any agreement, instrument or understanding, oral or written, to which it is
a Party or by which it may be bound, nor violate any material law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over it.

               (b) Hansen represents and warrants to ISI that: (i) Hansen has disclosed in writing to ISI
each patent or patent application (identifying the patent numbers or application serial numbers and
countries of prosecution) that is licensed to Hansen by a third

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

20

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

party, and the specific terms of any and all payment amounts that Hansen would be obligated
pay to such third party licensor if Hansen sublicensed such patent or patent application to ISI as
a Hansen Patent under this Cross License; (ii) Hansen has disclosed in writing to ISI each patent
or patent application (identifying the patent numbers or application serial numbers and countries
of prosecution) that is licensed to Hansen by a third party and for which Hansen does not have the
right to grant ISI sublicenses under the terms of this Cross License.

               (c) ISI represents and warrants to Hansen that: (i) ISI has disclosed in writing to Hansen
each patent or patent application (identifying the patent numbers or application serial numbers and
countries of prosecution) that is licensed to ISI by a third party, and the specific terms of any
and all payment amounts that ISI would be obligated pay to such third party licensor if ISI
sublicensed such patent or patent application to Hansen as an ISI Patent under this Cross License;
(ii) ISI has disclosed in writing to Hansen each patent or patent application (identifying the
patent numbers or application serial numbers and countries of prosecution) that is licensed to ISI
by a third party and for which ISI does not have the right to grant Hansen sublicenses under the
terms of this Cross License.

     8. LIMITATION OF LIABILITY

          NOTWITHSTANDING ANYTHING ELSE IN THIS CROSS LICENSE OR OTHERWISE, NEITHER PARTY SHALL BE
LIABLE TO THE OTHER PARTY OR TO ANY OTHER PERSON OR ENTITY WITH RESPECT TO ANY SUBJECT MATTER OF
THIS CROSS LICENSE, UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE
THEORY, FOR ANY (A) INCIDENTAL, SPECIAL, PUNITIVE (OTHER THAN STATUTORY DAMAGES AVAILABLE FOR
WILLFUL INFRINGEMENT) CONSEQUENTIAL OR INDIRECT DAMAGES, (B) DAMAGES RESULTING FROM LOSS OF SALE,
BUSINESS, PROFITS OR GOODWILL, (C) COST OF PROCUREMENT OF SUBSTITUTE GOODS OR TECHNOLOGY, EVEN IF
THE REMEDIES PROVIDED FOR IN THIS CROSS LICENSE FAIL OF THEIR ESSENTIAL PURPOSE AND EVEN IF EITHER
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OR PROBABILITY OF SUCH DAMAGES.

     9. MISCELLANEOUS 

          9.1 Assignment. This Cross License and the rights and obligations hereunder may not be
transferred or assigned by either party without the prior written consent of the other party;
provided that, either party may, without the other party’s prior written consent, assign or
transfer this Cross License and its rights and obligations hereunder in connection with an
Acquisition or Asset Transfer. Subject to the foregoing, this Cross License shall be binding on,
inure to the benefit of, and be enforceable by the Parties and their respective heirs, successors
and permitted assigns.

          9.2 Amendment and Waiver. Except as otherwise expressly provided herein, any provision
of this Cross License may be amended and the observance of any provision of this Cross License may
be waived (either generally or in any particular instance and either

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

21

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

retroactively or prospectively) only with the written consent of the parties. The failure of
either party to enforce its rights under this Cross License at any time for any period shall not be
construed as a waiver of rights.

          9.3 Governing Law and Legal Actions. This Cross License shall be governed by and
construed under the laws of California without regard to the conflicts of law provisions thereof.
The state and federal courts of the Northern District of California shall have exclusive
jurisdiction for disputes related to this Cross License, except as provided in Section 5.7, and the
parties hereby consent to the personal jurisdiction of the court.

          9.4 Headings. Headings and captions are for convenience only and are not to be used in
the interpretation of this Cross License.

          9.5 Notices. Any notice or other communication required or permitted to be made or
given to either party under this Cross License shall be deemed sufficiently made or given on the
date of delivery if delivered in person or by overnight commercial courier service with tracking
capabilities with costs prepaid, or five (5) days after the date of mailing if sent by certified
first class mail, return receipt requested and postage prepaid, to the address of the parties (and
addressed to the representative) set forth below or such other address (or representative) as may
be given from time to time under the terms of this notice provision:

	 	 	 
	If to ISI:

	 	If to Hansen:
	950 Kifer Road,

	 	380 North Bernardo Avenue
	Sunnyvale, California 94086

	 	Mountain View, California 94043
	Attention: General Counsel

	 	Attention: Vice President of Intellectual
	Telephone: (408) 523-2100

	 	Property
and Legal Affairs

	Facsimile: (408) 523-1390

	 	Telephone: (650) 406-5800
	 

	 	Facsimile: (650) 404-5901
	 
	 	 
	With a copy (which shall not constitute notice) to:

	 	With a copy (which shall not
constitute notice) to:
	 
	Wilson Sonsini Goodrich & Rosati

	 	Cooley Godward LLP
	650 Page Mill Road

	 	Five Palo Alto Square
	Palo Alto, California 94304-1050

	 	3000 El Camino Real
	Attention: Casey McGlynn

	 	Palo Alto, California 94306
	Telephone: (650) 493-9300

	 	Attention: Barclay Kamb
	Facsimile: (650) 493-6811

	 	Telephone: (650) 843-5000
	 

	 	Facsimile: (650) 849-7400

          9.6 Severability. If any provision of this Cross License is held to be illegal or
unenforceable, that provision shall be limited or eliminated to the minimum extent necessary so
that this Cross License shall otherwise remain in full force and effect and enforceable.

          9.7 Relationship of Parties. Each party acknowledges and agrees that the other party
is an independent contractor in the performance of each and every part of this Cross

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

22

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

License and is solely responsible for all of its employees, contractors and agents and its
labor costs and expenses arising in connection therewith. The parties are not partners, joint
venturers, franchiser-franchisee or otherwise affiliated, and neither has any right or authority to
make any statements, representations or commitments of any kind, or to take any action, which shall
be binding on the other party, without the prior written consent of the other party. Without
limiting the foregoing, the parties agree that this Cross License is not intended to create a
franchise within the meaning of any applicable statute.

          9.8 Counterparts. This Cross License may be executed in counterparts, each of which
shall be deemed an original but all of which together shall constitute one and the same instrument.
This Cross License may be executed by facsimile with the original signatures following promptly by
one of the methods of delivery or mailing set forth in Section 9.5 above.

          9.9 Entire Agreement. The terms and conditions contained in this Cross License, the
Share Transfer Agreement and Hansen Investor Rights Agreement constitute the entire agreement
between the parties and supersede all previous agreements and understandings, whether oral or
written, between the parties with respect to the subject matter hereof.

******

     IN WITNESS WHEREOF the parties hereto have executed this Cross License as of the Effective
Date.

	 	 	 	 	 	 	 	 	 
	INTUITIVE SURGICAL, INC.	 	HANSEN MEDICAL, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Lonnie M. Smith
	 	By:
	 	/s/ Frederic H. Moll	 	 
	 

	 	 
	 	 	 	 	 	 
	Title:

	 	President and CEO
	 	Title:
	 	CEO	 	 
	Date:

	 	September 1, 2005
	 	Date:
	 	September 1, 2005	 	 

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

23

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

EXHIBIT A

Share Transfer Agreement

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

1

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

EXHIBIT B

Investors Rights Agreement

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

1

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

EXHIBIT C

New Product Procedure

     1. If a Party (the “Initiating Party”) initiates pursuant to Section 5.7 of the Agreement the
procedure under this Exhibit C as to a new product of such Initiating Party that it plans to sell
for a use outside its licensed field (the “Subject Product”), the Parties shall then proceed under
the provisions of this Exhibit C, cooperatively and in good faith. Such Initiating Party shall
first provide a demonstration of the Subject Product to the other Party (the “Responding Party”)
and its legal representatives, under an appropriate confidential disclosure agreement entered into
by the Parties (and any such representatives).

     2. Such Responding Party then has up to [*] business days to provide to the Initiating Party a
list of written questions regarding the construction and operation of the Subject Product, and the
Initiating Party shall provide its answers to such questions, in confidence under the confidential
disclosure agreement, within [*] business days from its receipt of questions.

     3. Within [*] business days after timely receipt of the Initiating Party’s answers to the
written questions submitted under paragraph 2 above, or if no answers were requested or timely
received, then within [*] days after the demonstration, the Responding Party shall either: (a)
provide the Initiating Party with written notice (a “Non-Infringement Notice”) that such Responding
Party concludes that the Subject Product would not infringe any patents owned or controlled by such
Responding Party, or any claims or any claims in any patent applications owned or controlled by
such Responding Party were such applications to issue as patents; or (b) provide the Initiating
Party with written notice (an “Infringement Notice”) that such Responding Party believes that the
Subject Product would infringe one or more of the patents owned or controlled by such Responding
Party, or any claims or any claims in any patent applications owned or controlled by such
Responding Party were such applications to issue as patents, which notice shall include details of
such allegation and copies of the asserted patents or patent applications and shall provide the
detailed analysis for the basis for such Party’s belief that the Subject Product infringes that
indicated patents or would infringe the indicated patent applications (if such applications
issued).

     4. If the Responding Party provides an Infringement Notice as to the Subject Product, then the
Parties shall meet promptly after such notice is received, and the Parties shall discuss
cooperatively and in good faith the infringement issue covered by the Infringement Issue for up to
[*] business days and shall amicably and in good faith resolve the infringement issue by [*].

     5. If the Parties are unable to reach agreement after such [*] business day period, then the
Parties shall proceed under the provisions of Section 5.7(b) to resolve the question of whether the
Subject Product infringes one or more claims of the identified patents, including

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

CONFIDENTIAL

CERTAIN INFORMATION HAS BEEN REDACTED

CONFIDENTIAL TREATMENT REQUESTED

addressing and resolving any defenses that the Initiating Party may have to the assertion of
infringement (such as invalidity or unenforceability).

     7. [sic]The arbitrators may impose monetary sanctions (payable to the Responding Party) if the
Initiating Party does not provide all relevant information relating to the Subject Product
requested by the Responding Party or the arbitrators (including demonstrations of the product), or
otherwise cooperate fully with them. Similarly, the arbitrators may impose monetary sanctions
(payable to the Initiating Party) if the Responding Party does not provide all relevant information
relating to the subject patents requested by the Initiating Party or the arbitrators, or otherwise
cooperate fully with them. Such arbitration shall determine whether the Subject Product would
infringe the Responding Party’s patents that are the subject of the Infringement Notice. The
arbitrators will set forth in writing their decision regarding infringement or non-infringement of
such patents by the Subject Product, including the specific patents and claims analyzed by the
arbitrators and an explanation of the bases for such decision. Determinations made by the
arbitrators are binding upon the Parties, and cannot be appealed or litigated in federal court.
Notwithstanding the forgoing, if the arbitrators determine that the Subject Product infringes the
Responding Party’s patents and the Initiating Party does not cease the infringement within [*] days
after the arbitrators’ decision or in the future sells the Subject Product, then the Responding
Party may seek damages and other remedies by litigation in court in accordance with Section 9.3,
and to have the court determine if the Initiating Party is selling the Subject Product in violation
of the arbitrators’ determination of infringement. The Responding Party may submit the arbitrators’
decision in such litigation. If such litigation results in a judgment that the Initiating Party is
selling the Subject Product in violation of the arbitrators’ determination of infringement from
which no appeal can be or is taken, then the Initiating Party will have committed a “Material
Breach,” for which the Responding Party may terminate this Agreement within 30 days by written
notice to the Initiating Party.

     8. In the case of an arbitration under paragraph 7 above, the Responding Party shall pay all
arbitration expenses for the aspects of the arbitration that relate to the allegations of
infringement, the Initiating Party shall pay all arbitration expenses for the aspects of the
arbitration that relate to any of the Initiating Party’s asserted defenses, and each Party shall
pay its own legal expenses including deposition expenses and other discovery expenses related to
these proceedings. If the arbitration results in a determination that the Initiating Party
infringes the asserted patents, then the Responding Party shall be entitled to reimbursement the
arbitration expenses that it paid. If the arbitration results in a determination that the
Initiating Party does not infringe the asserted patents (including because of defenses of the
Initiating Party or simply due to non-infringement), then the Initiating Party shall be entitled to
reimbursement the arbitration expenses that it paid.

[*] Confidential information in this Exhibit has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.

-2-exv10w1

 

EXHIBIT 10.1

CROSSTEX ENERGY, INC.

LONG-TERM INCENTIVE PLAN

(Amended and Restated Effective as of September 6, 2006)

ARTICLE I. ESTABLISHMENT AND PURPOSE

     1.1 Establishment. The Crosstex Energy, Inc. Long-Term Incentive Plan (the “Plan”) was originally
approved by the Board of Directors of Crosstex Energy, Inc., a Delaware corporation, to be
effective December 31, 2003. In furtherance of the purposes of said plan and in order to amend
said plan in certain respects, the plan is hereby amended and restated in its entirety as set forth
in this document.

     1.2 Purpose. The purposes of the Plan are to attract able persons to enter the employ of the
Company, to encourage Employees to remain in the employ of the Company and to provide motivation to
Employees to put forth maximum efforts toward the continued growth, profitability and success of
the Company, by providing incentives to such persons through the ownership and/or performance of
the Common Stock of Crosstex. A further purpose of the Plan is to provide a means through which
the Company may attract able persons to become directors of the Company and to provide such
individuals with incentive and reward opportunities. Toward these objectives, Awards may be
granted under the Plan to Employees and Outside Directors on the terms and subject to the
conditions set forth in the Plan.

     1.3 Effectiveness. This amended and restated Plan shall become effective as of September 6, 2006,
following its adoption by the Board, provided it is duly approved by the holders of at least a
majority of the shares of Common Stock present or represented and entitled to vote at a meeting of
the stockholders of Crosstex duly held in accordance with applicable law within twelve months after
the date of adoption of the Plan by the Board. If the amended and restated Plan is not so
approved, the amended and restated Plan shall not be effective, any Award granted under the amended
and restated Plan shall be null and void, and the Plan as in effect prior to its amendment (and
grants made under said plan) shall remain in full force and effect.

ARTICLE II. DEFINITIONS

     2.1 Affiliate. “Affiliate” means, with respect to any Person, any other Person that directly or
indirectly through one or more intermediaries controls, is controlled by or is under common control
with, the Person in question. As used herein, the term “control” means the possession, direct or
indirect, of the power to direct or cause the direction of the management and policies of a Person,
whether through ownership of voting securities, by contract or otherwise. With respect to an
Incentive Stock Option, “Affiliate” means a “parent corporation” or a “subsidiary corporation” of
Crosstex, as those terms are defined in Section 424(e) and (f) of the Code.

     2.2 Award. “Award” means an award granted to a Participant in the form of an Option or Restricted
Stock. All Awards shall be granted by, confirmed by, and subject to the terms of, an Award
Agreement.

     2.3 Award Agreement. “Award Agreement” means a written agreement between Crosstex and a
Participant that sets forth the terms, conditions, restrictions and/or limitations applicable to an
Award.

     2.4 Board. “Board” means the Board of Directors of Crosstex.

 Page 1 of 13 

 

     2.5 Cause. “Cause” means (i) Participant has failed to perform the duties assigned to him and such
failure has continued for thirty (30) days following delivery by the Company of written notice to
Participant of such failure, (ii) Participant has been convicted of a felony or misdemeanor
involving moral turpitude, (iii) Participant has engaged in acts or omissions against the Company
constituting dishonesty, breach of fiduciary obligation, or intentional wrongdoing or misfeasance
or (iv) Participant has acted intentionally or in bad faith in a manner that results in a material
detriment to the assets, business or prospects of the Company.

     2.6 Change of Control. “Change of Control” shall have the meaning set forth in Section 9.1.

     2.7 Code. “Code” means the Internal Revenue Code of 1986, as amended from time to time, including
regulations thereunder and successor provisions and regulations thereto.

     2.8 Committee. “Committee” means (i) with respect to the application of this Plan to Employees,
the Compensation Committee of the Board or such other committee of the Board as may be designated
by the Board to administer the Plan, which committee shall consist of two or more non-employee
directors, each of whom is both a “non-employee director” under Rule 16b-3 of the Exchange Act and
an “outside director” under Section 162(m) of the Code, and (ii) with respect to the application of
this Plan to an Outside Director, the Board. To the extent that no Committee exists that has the
authority to administer the Plan, the functions of the Committee shall be exercised by the Board.
If for any reason the appointed Committee does not meet the requirements of Rule 16b-3 or Section
162(m) of the Code, such noncompliance with such requirements shall not affect the validity of
Awards, grants, interpretations or other actions of the Committee.

     2.9 Common Stock. “Common Stock” means the common stock, $.01 par value per share, of Crosstex, or
any stock or other securities of Crosstex hereafter issued or issuable in substitution or exchange
for the Common Stock.

     2.10 Company. “Company” means Crosstex and its Affiliates.

     2.11 Consultant . “Consultant” means an individual performing services for Crosstex or an Affiliate who is treated
for tax purposes as an independent contractor at the time of performance of the services.

     2.12 Crosstex. “Crosstex” means Crosstex Energy, Inc., a Delaware corporation, or any successor
thereto.

     2.13 Effective Date. “Effective Date” means the date this amended and restated Plan becomes
effective as provided in Section 1.3.

     2.14 Employee. “Employee” means an employee of the Company; provided, however, that the term
Employee does not include an Outside Director or a Consultant.

     2.15 Exchange Act. “Exchange Act” means the Securities Exchange Act of 1934, as amended.

     2.16 Fair Market Value. “Fair Market Value” means the closing sales price of a share of Common
Stock on the applicable date (or if there is no trading in the Common Stock on such date, on the
next preceding date on which there was trading) as reported in The Wall Street Journal (or other
reporting service approved by the Committee). In the event the Common Stock is not publicly traded
at the time a

 Page 2 of 13 

 

determination of fair market value is required to be made hereunder, the
determination of fair market value shall be made in good faith by the Committee.

     2.17 Grant Date. “Grant Date” means the date an Award is granted by the Committee.

     2.18 Incentive Stock Option. “Incentive Stock Option” means an Option that is intended to meet the
requirements of Section 422(b) of the Code.

     2.19 Nonqualified Stock Option. “Nonqualified Stock Option” means an Option that is not an
Incentive Stock Option.

     2.20 Option. “Option” means an option to purchase shares of Common Stock granted to a Participant
pursuant to Article VII. An Option may be either an Incentive Stock Option or a Nonqualified Stock
Option, as determined by the Committee.

     2.21 Outside Director. “Outside Director” means a “non-employee director” of the Company, as
defined in Rule 16b-3.

     2.22 Participant. “Participant” means an Employee, Consultant or Outside Director to whom an Award
has been granted under the Plan.

     2.23 Person. “Person” means an individual or a corporation, limited liability company,
partnership, joint venture, trust, unincorporated organization, association, government agency or
political subdivision thereof or other entity.

     2.24 Plan. “Plan” means this Crosstex Energy, Inc. Long-Term Incentive Plan, as amended from time
to time.

     2.25 Restricted Stock. “Restricted Stock” means shares of Common Stock granted to a Participant
pursuant to Article VIII, which are subject to such restrictions as may be determined by the
Committee. Restricted Stock shall constitute issued and outstanding shares of Common Stock for all
corporate purposes.

     2.26 Restriction Period. “Restriction Period” means the period of time established by the
Committee at the time of a grant of Restricted Stock during which the Restricted Stock shall be
fully or partially forfeitable.

     2.27 Rule 16b-3. “Rule 16b-3” means Rule 16b-3 promulgated by the SEC under the Exchange Act, or
any successor rule or regulation thereto as in effect from time to time.

ARTICLE III. PLAN ADMINISTRATION

     3.1 Plan Administrator. The Plan shall be administered by the Committee. The Committee may
delegate some or all of its power to the Chief Executive Officer or other executive officer of the
Company as the Committee deems appropriate; provided, that (i) the Committee may not delegate its
power with regard to the grant of an Award to any person who is a “covered employee” within the
meaning of Section 162(m) of the Code or who, in the Committee’s judgment, is likely to be a
covered employee at any time during the period an Award to such employee would be outstanding, and
(ii) the Committee may not delegate its power with regard to the selection for participation in the
Plan of an officer or other person subject to Section 16 of the Exchange Act or decisions
concerning the timing, pricing or amount of an Award to such an officer or other person.

 Page 3 of 13 

 

     3.2 Authority of Administrator. The Committee shall have total and exclusive responsibility to
control, operate, manage and administer the Plan in accordance with its terms. The Committee shall
have all the authority that may be necessary or helpful to enable it to discharge its
responsibilities with respect to the Plan. Without limiting the generality of the preceding
sentence, but subject to the limitation that none of the enumerated powers of the Committee shall
be deemed to include any action that would cause a tax to be imposed on a
Participant pursuant to section 409A of the Code, the Committee shall have the exclusive right to:
(i) interpret the Plan and the Award Agreements executed hereunder; (ii) determine eligibility for
participation in the Plan; (iii) decide all questions concerning eligibility for, and the amount
of, Awards granted under the Plan; (iv) construe any ambiguous provision of the Plan or any Award
Agreement; (v) prescribe the form of the Award Agreements embodying Awards granted under the Plan;
(vi) correct any defect, supply any omission or reconcile any inconsistency in the Plan or any
Award Agreement; (vii) issue administrative guidelines as an aid to administering the Plan and make
changes in such guidelines as the Committee from time to time deems proper; (viii) make regulations
for carrying out the Plan and make changes in such regulations as the Committee from time to time
deems proper; (ix) determine whether Awards should be granted singly or in combination; (x) to the
extent permitted under the Plan, grant waivers of Plan terms, conditions, restrictions and
limitations; (xi) accelerate the exercise, vesting or payment of an Award when such action or
actions would be in the best interests of the Company; (xii) grant Awards in replacement of Awards
previously granted under the Plan or any other employee benefit plan of the Company; and (xiii)
take any and all other actions the Committee deems necessary or advisable for the proper operation
or administration of the Plan.

     3.3 Discretionary Authority. The Committee shall have full discretionary authority in all matters
related to the discharge of its responsibilities and the exercise of its authority under the Plan,
including, without limitation, its construction of the terms of the Plan and its determination of
eligibility for participation and Awards under the Plan. The decisions of the Committee and its
actions with respect to the Plan shall be final, conclusive and binding on all persons having or
claiming to have any right or interest in or under the Plan, including Participants and their
respective estates, beneficiaries and legal representatives.

     3.4 Liability; Indemnification. No member of the Committee nor any person to whom authority has
been delegated, shall be personally liable for any action, interpretation or determination made in
good faith with respect to the Plan or Awards granted hereunder, and each member of the Committee
(or delegatee of the Committee) shall be fully indemnified and protected by Crosstex with respect
to any liability he or she may incur with respect to any such action, interpretation or
determination, to the extent permitted by applicable law.

ARTICLE IV. SHARES SUBJECT TO THE PLAN

     4.1 Available Shares. The maximum number of shares of Common Stock that shall be available for
grant of Awards under the Plan shall not exceed a total of 1,530,000, subject to adjustment as
provided in Sections 4.2 and 4.3; provided, however, the maximum number of shares of Common Stock
for which Options may be granted under the Plan to any one Participant during a calendar year is
100,000. Shares of Common Stock issued pursuant to the Plan may be shares of original issuance or
treasury shares or a combination of the foregoing, as the Committee, in its absolute discretion,
shall from time to time determine.

     4.2 Adjustments for Recapitalizations and Reorganizations.

     (a) The shares with respect to which Awards may be granted under the Plan are shares of
Common Stock as presently constituted, but if, and whenever, prior to the expiration or

 Page 4 of 13 

 

satisfaction of an Award theretofore granted, Crosstex shall effect a subdivision or
consolidation of shares of Common Stock or the payment of a stock dividend on Common Stock
in the form of Crosstex Common Stock without receipt of consideration by Crosstex, the
number of shares of
Common Stock with respect to which such Award may thereafter be exercised or satisfied, as
applicable, (i) in the event of an increase in the number of outstanding shares, shall be
proportionately increased, and the exercise price per share shall be proportionately
reduced, and (ii) in the event of a reduction in the number of outstanding shares, shall be
proportionately reduced, and the exercise price per share shall be proportionately
increased.

     (b) If Crosstex recapitalizes or otherwise changes its capital structure, thereafter
upon any exercise or satisfaction, as applicable, of an Award theretofore granted the
Participant shall be entitled to (or entitled to purchase, if applicable) under such Award,
in lieu of the number of shares of Common Stock then covered by such Award, the number and
class of shares of stock or other securities to which the Participant would have been
entitled pursuant to the terms of the recapitalization if, immediately prior to such
recapitalization, the Participant had been the holder of record of the number of shares of
Common Stock then covered by such Award.

     (c) In the event of changes in the outstanding Common Stock by reason of a
reorganization, merger, consolidation, combination, separation (including a spin-off or
other distribution of stock or property), exchange, or other relevant change in
capitalization occurring after the date of grant of any Award and not otherwise provided for
by this Section 4.2, any outstanding Awards and any Award Agreements evidencing such Awards
shall be subject to adjustment by the Committee in its absolute discretion as to the number,
price and kind of shares or other consideration subject to, and other terms of, such Awards
to reflect such changes in the outstanding Common Stock.

     (d) In the event of any changes in the outstanding Common Stock provided for in this
Section 4.2, the aggregate number of shares available for grant of Awards under the Plan may
be equitably adjusted by the Committee, whose determination shall be conclusive. Any
adjustment provided for in this Section 4.2 shall be subject to any required stockholder
action.

     4.3 Adjustments for Awards. The Committee shall have full discretion to determine the manner in
which shares of Common Stock available for grant of Awards under the Plan are counted. Without
limiting the discretion of the Committee under this Section 4.3, unless otherwise determined by the
Committee, the following rules shall apply for the purpose of determining the number of shares of
Common Stock available for grant of Awards under the Plan:

     (a) Options and Restricted Stock. The grant of Options and Restricted Stock shall
reduce the number of shares available for grant of Awards under the
Plan by the number of shares subject to such Award.

     (b) Termination. If any Award referred to in paragraph (a) above is canceled or
forfeited, or terminates, expires or lapses for any reason, the shares then subject to such
Award shall again be available for grant of Awards under the Plan.

     (c) Payment of Exercise Price and Withholding Taxes. If previously acquired shares of
Common Stock are used to pay the exercise price of an Award, the number of shares available
for grant of Awards under the Plan shall not be increased by the number of shares delivered
as payment of such exercise price. If previously acquired shares of Common Stock are used
to pay withholding taxes payable upon exercise, vesting or payment of an Award, or shares

 Page 5 of 13 

 

of
Common Stock that would be acquired upon exercise, vesting or payment of an Award are
withheld to pay withholding taxes payable upon exercise, vesting or payment of such Award,
the
number of shares available for grant of Awards under the Plan shall not be increased by
the number of shares delivered or withheld as payment of such withholding taxes.

     (d) Fractional Shares. If any such adjustment would result in a fractional security
being (i) available under the Plan, such fractional security shall be disregarded or (ii)
subject to an Award, Crosstex shall pay the holder of such Award, in connection with the
first vesting, exercise or settlement of such Award in whole or in part occurring after such
adjustment, an amount in cash determined by multiplying (x) the fraction of such security
(rounded to the nearest hundredth) by (y) the excess, if any, of the Fair Market Value on
the vesting, exercise or settlement date over the exercise price, if any, of such Award.

ARTICLE V. ELIGIBILITY

     All Employees, Consultants and Outside Directors are eligible to participate in the Plan. The
Committee shall recommend, from time to time, Participants from those Employees, Consultants and
Outside Directors who, in the opinion of the Committee, can further the Plan purposes. Once a
Participant is recommended for an Award by the Committee, the Committee shall determine the type
and size of Award to be granted to the Participant and shall establish in the related Award
Agreement the terms, conditions, restrictions and/or limitations applicable to the Award, in
addition to those set forth in the Plan and the administrative rules and regulations, if any,
established by the Committee.

ARTICLE VI. FORM OF AWARDS

     Awards may, at the Committee’s sole discretion, be granted under the Plan in the form of
Options pursuant to Article VII or Restricted Stock pursuant to Article VIII or a combination
thereof. All Awards shall be subject to the terms, conditions, restrictions and limitations of the
Plan. The Committee may, in its absolute discretion, subject any Award to such other terms,
conditions, restrictions and/or limitations (including, but not limited to, the time and conditions
of exercise, vesting or payment of an Award and restrictions on transferability of any shares of
Common Stock issued or delivered pursuant to an Award), provided they are not inconsistent with the
terms of the Plan. Awards under a particular Article of the Plan need not be uniform, and Awards
under more than one Article of the Plan may be combined into a single Award Agreement. Any
combination of Awards may be granted at one time and on more than one occasion to the same
Participant.

ARTICLE VII. OPTIONS

     7.1 General. Awards may be granted to Employees, Consultants and Outside Directors in the form of
Options. Options granted under the Plan may be Incentive Stock Options or Nonqualified Stock
Options, or a combination of both; provided, however, that Incentive Stock Options may be granted
only to Employees.

     7.2 Terms and Conditions of Options. An Option shall be exercisable in whole or in such
installments and at such times as may be determined by the Committee. The price at which a share
of Common Stock may be purchased upon exercise of a Nonqualified Stock Option shall be determined
by the Committee, but such exercise price shall not be less than 100% of the Fair Market Value per
share of Common Stock on the Grant Date. Except as otherwise provided in Section 7.3, the term of
each Option shall be as specified by the Committee; provided, however, that, no Options shall be
exercisable later than ten years from the Grant Date.
Options may be granted with respect to Restricted Stock or shares of Common Stock that are not
Restricted Stock, as determined by the Committee in its absolute discretion.

 Page 6 of 13 

 

     7.3 Restrictions Relating to Incentive Stock Options. Options granted in the form of Incentive
Stock Options shall, in addition to being subject to the terms and conditions of Section 7.2,
comply with Section 422(b) of the Code. Accordingly, no Incentive Stock Options shall be granted
later than ten years from the date of adoption of the Plan by the Board. To the extent that the
aggregate Fair Market Value (determined at the time the respective Incentive Stock Option is
granted) of Common Stock with respect to which Incentive Stock Options are exercisable for the
first time by an individual during any calendar year under all incentive stock option plans of
Crosstex and its Affiliates exceeds $100,000, such excess Incentive Stock Options shall be treated
as Nonqualified Stock Options. The Committee shall determine, in accordance with the applicable
provisions of the Code, which of a Participant’s Incentive Stock Options will not constitute
Incentive Stock Options because of such limitation and shall notify the Participant of such
determination as soon as practicable after such determination. The price at which a share of
Common Stock may be purchased upon exercise of an Incentive Stock Option shall be determined by the
Committee, but such exercise price shall not be less than 100% of the Fair Market Value of a share
of Common Stock on the Grant Date. No Incentive Stock Option shall be granted to an Employee under
the Plan if, at the time such Option is granted, such Employee owns stock possessing more than 10%
of the total combined voting power of all classes of stock of Crosstex or an Affiliate, within the
meaning of Section 422(b)(6) of the Code, unless (i) on the Grant Date of such Option, the exercise
price of such Option is at least 110% of the Fair Market Value of the Common Stock subject to the
Option and (ii) such Option by its terms is not exercisable after the expiration of five years from
the Grant Date of the Option.

     7.4 Additional Terms and Conditions. The Committee may subject any Award of an Option to such
other terms, conditions, restrictions and/or limitations as it determines are necessary or
appropriate, provided they are not inconsistent with the Plan.

     7.5 Exercise of Options. Subject to the terms and conditions of the Plan, Options shall be
exercised by the delivery of a written notice of exercise to Crosstex, setting forth the number of
shares of Common Stock with respect to which the Option is to be exercised, accompanied by full
payment for such shares.

          Upon exercise of an Option, the exercise price of the Option shall be payable to Crosstex in
full either: (i) in cash or an equivalent acceptable to the Committee, or (ii) in the absolute
discretion of the Committee and in accordance with any applicable administrative guidelines
established by the Committee, by tendering one or more previously acquired nonforfeitable shares of
Common Stock that have been owned a minimum of 6 months having an aggregate Fair Market Value at
the time of exercise equal to the total exercise price (including an actual or deemed multiple
series of exchanges of such shares), or (iii) in a combination of the forms of payment specified in
clauses (i) and (ii) above.

          From and after such time as Crosstex registers the Common Stock under Section 12 of the
Exchange Act, payment of the exercise price of an Option may also be made, in the absolute
discretion of the Committee, by delivery to Crosstex or its designated agent of an executed
irrevocable option exercise form together with irrevocable instructions to a broker-dealer to sell
or margin a sufficient portion of the shares with respect to which the Option is exercised and
deliver the sale or margin loan proceeds directly to Crosstex to pay the exercise price and any
required withholding taxes.

          As soon as reasonably practicable after receipt of written notification of exercise of an
Option and full payment of the exercise price and any required withholding taxes, Crosstex shall
deliver to the Participant, in the Participant’s name, a stock certificate or certificates in an
appropriate amount based upon the number of shares of Common Stock purchased under the Option.

 Page 7 of 13 

 

     7.6 Termination of Employment or Service. Each Award Agreement embodying the Award of an Option
shall set forth the extent to which the Participant shall have the right to exercise the Option
following termination of the Participant’s employment or service with the Company. Such provisions
shall be determined by the Committee in its absolute discretion, need not be uniform among all
Options granted under the Plan and may reflect distinctions based on the reasons for termination of
employment or service. In the event a Participant’s Award Agreement embodying the award of an
Option does not set forth such termination provisions, the following termination provisions shall
apply with respect to such Award:

     (a) Death, Disability or Retirement. If the employment or service of a Participant
shall terminate by reason of death, permanent and total disability (within the meaning of
Section 22(e)(3) of the Code) or retirement with the approval of the Committee on or after
the Participant’s attainment of age 60, each outstanding Option held by the Participant
shall become vested and may be exercised until the earlier of (i) the expiration of one year
(three months in the case of an Incentive Stock Option held by a retired Participant) from
the date of such termination of employment or service, or (ii) the expiration of the term of
such Option.

     (b) Other Termination. If the employment or service of a Participant shall terminate
for any reason other than a reason set forth in paragraph (a) above or paragraph (c) below,
whether on a voluntary or involuntary basis, each outstanding Option held by the Participant
may be exercised, to the extent then vested, until the earlier of (i) the expiration of
three months from the date of such termination of employment or service, or (ii) the
expiration of the term of such Option.

     (c) Termination for Cause. Notwithstanding paragraphs (a) and (b) above, if the
employment or service of a Participant is terminated for Cause, all outstanding Options held
by the Participant shall immediately be forfeited to the Company and no additional exercise
period shall be allowed, regardless of the vested status of the Option.

ARTICLE VIII. RESTRICTED STOCK

     8.1 General. Awards may be granted to Employees, Consultants and Outside Directors in the form of
Restricted Stock. Restricted Stock shall be awarded in such numbers and at such times as the
Committee shall determine.

     8.2 Restriction Period. At the time an Award of Restricted Stock is granted, the Committee shall
establish the Restriction Period applicable to such Restricted Stock. Each Award of Restricted
Stock may have a different Restriction Period, in the discretion of the Committee. The Restriction
Period applicable to a particular Award of Restricted Stock shall not be changed except as
permitted by Article IV or Section 8.3 of this Article.

     8.3 Other Terms and Conditions. Restricted Stock awarded to a Participant under the Plan shall be
represented by a stock certificate registered in the name of the Participant or, at the option of
Crosstex, in the name of a nominee of Crosstex. Subject to the terms and conditions of the Award
Agreement, a Participant to whom Restricted Stock has been awarded shall have the right to receive
dividends thereon during the Restriction Period, to vote the Restricted Stock and to enjoy all
other stockholder rights with respect thereto, except that (i) the Participant shall not be
entitled to possession of the stock certificate representing the Restricted Stock until the
Restriction Period shall have expired, (ii) Crosstex shall retain custody of the Restricted Stock
during the Restriction Period, (iii) the Participant may not sell, transfer, pledge, exchange,
hypothecate or otherwise dispose of the Restricted Stock during the Restriction Period, and (iv) a
breach of the terms and conditions established by the Committee

 Page 8 of 13 

 

pursuant to the Award of the
Restricted Stock shall cause a forfeiture of the Restricted Stock. At the time of an Award of
Restricted Stock, the Committee may, in its absolute discretion, prescribe additional terms,
conditions, restrictions and/or limitations applicable to the Restricted Stock, including, but not
limited to, rules pertaining to the termination of employment or service by reason of death,
permanent and total disability, retirement or otherwise, of a Participant prior to expiration of
the Restriction Period.

     8.4 Payment for Restricted Stock. A Participant shall not be required to make any payment for
Restricted Stock awarded to the Participant, except to the extent otherwise required by the
Committee or by applicable law.

     8.5 Miscellaneous. Nothing in this Article shall prohibit the exchange of shares of Restricted
Stock issued under the Plan pursuant to a plan of reorganization for stock or securities of
Crosstex or another corporation that is a party to the reorganization, but the stock or securities
so received for shares of Restricted Stock shall, except as provided in Article IV or IX, become
subject to the restrictions applicable to the Award of such Restricted Stock. Any shares of stock
received as a result of a stock split or stock dividend with respect to shares of Restricted Stock
shall also become subject to the restrictions applicable to the Award of such Restricted Stock.

ARTICLE IX. CHANGE OF CONTROL

     9.1 Definition of Change of Control. A “Change of Control” means: (a) the consummation of a merger
or consolidation of the Company with or into another entity or any other transaction, if Persons
who were not shareholders of the Company immediately prior to such merger, consolidation or other
transaction beneficially own immediately after such merger, consolidation or other transaction 50%
or more of the voting power of the outstanding securities of each of (i) the continuing or
surviving entity and (ii) any direct or indirect parent entity of such continuing or surviving
entity; (b) the sale, transfer or other disposition of all or substantially all of the Company’s
assets; (c) a change in the composition of the Board as a result of which fewer than 50% of the
incumbent directors are directors who either (i) had been directors of Crosstex on the date 12
months prior to the date of the event that may constitute a Change of Control (the “original
directors”) or (ii) were elected, or nominated for election, to the Board with the affirmative
votes of at least a majority of the aggregate of the original directors who were still in office at
the time of the election or nomination and the directors whose election or nomination was
previously so approved; or (d) any transaction as a result of which any Person is the “beneficial
owner” (as defined in Rule 13d-3 under the Exchange Act),
directly or indirectly, of securities of the Company representing at least 50% of the total voting
power represented by the Company’s then outstanding voting securities.

     9.2 Effect on Outstanding Awards. Immediately prior to a Change of Control, all Awards shall
automatically vest and become payable or exercisable, as the case may be, in full. In this regard,
all Restriction Periods shall terminate. The phrase “Immediately prior to a Change of Control”
shall be understood to mean sufficiently in advance of a Change of Control to permit Participants
to take all steps reasonably necessary to exercise an Award, if applicable, and to deal with the
Common Stock underlying all Awards so that all Awards and Common Stock issuable with respect
thereto may be treated in the same manner as the shares of stock of other stockholders in
connection with the Change of Control.

 Page 9 of 13 

 

ARTICLE X. AMENDMENT AND TERMINATION

     10.1 Plan Amendment and Termination. The Board may at any time suspend, terminate, amend or modify
the Plan, in whole or in part; provided, however, that no amendment or modification of the Plan
shall become effective without the approval of such amendment or modification by the stockholders
of Crosstex (i) if such amendment or modification increases the maximum number of shares subject to
the Plan (except as provided in Article IV) or changes the designation or class of persons eligible
to receive Awards under the Plan, or (ii) if counsel for Crosstex determines that such approval is
otherwise required by or necessary to comply with applicable law. The Plan shall terminate upon
the earlier of (i) the termination of the Plan by the Board, or (ii) the expiration of ten years
from the Effective Date. Upon termination of the Plan, the terms and provisions of the Plan shall,
notwithstanding such termination, continue to apply to Awards granted prior to such termination.
No suspension, termination, amendment or modification of the Plan shall adversely affect in any
material way any Award previously granted under the Plan, without the consent of the Participant
(or the permitted transferee) holding such Award.

     10.2 Award Amendment. The Board may amend the terms of any outstanding Award granted pursuant to
this Plan, but no such amendment shall adversely affect in any material way the Participant’s (or a
permitted transferee’s) rights under an outstanding Award without the consent of the Participant
(or the permitted transferee) holding such Award; provided, however, that no amendment shall be
made that would cause the exercise price of an Option to be less than the Fair Market Value of the
Common Stock subject to the Option on the Grant Date.

ARTICLE XI. MISCELLANEOUS

     11.1 Award Agreements. After the Committee grants an Award under the Plan to a Participant,
Crosstex and the Participant shall enter into an Award Agreement setting forth the terms,
conditions, restrictions and/or limitations applicable to the Award and such other matters as the
Committee may determine to be appropriate. The terms and provisions of the respective Award
Agreements need not be identical. All Award Agreements shall be subject to the provisions of the
Plan, and in the event of any conflict between an Award Agreement and the Plan, the terms of the
Plan shall govern.

     11.2 Listing Conditions.

     (a) As long as the Common Stock is listed on a national securities exchange or system
sponsored by a national securities association, the issuance of any shares of Common Stock
pursuant to an Award shall be conditioned upon such shares being listed on such exchange or
system. Crosstex shall have no obligation to issue such shares unless and until such shares
are so listed, and the right to exercise any Option or other Award with respect to such
shares shall be suspended until such listing has been effected.

     (b) If at any time counsel to Crosstex or its Affiliates shall be of the opinion that
any sale or delivery of shares of Common Stock pursuant to an Award is or may in the
circumstances be unlawful or result in the imposition of excise taxes on Crosstex or its
Affiliates under the statutes, rules or regulations of any applicable jurisdiction, Crosstex
or its Affiliates shall have no obligation to make such sale or delivery, or to make any
application or to effect or to maintain any qualification or registration under the
Securities Act of 1933, as amended, or otherwise, with respect to shares of Common Stock or
Awards, and the right to exercise any Option or other Award shall be suspended until, in the
opinion of said counsel, such sale or delivery shall be lawful or will not result in the
imposition of excise taxes on Crosstex or its Affiliates.

 Page 10 of 13 

 

     (c) Upon termination of any period of suspension under this Section 11.2, any Award
affected by such suspension which shall not then have expired or terminated shall be
reinstated as to all shares available before such suspension and as to shares which would
otherwise have become available during the period of such suspension, but no such suspension
shall extend the term of any Award.

     11.3 Additional Conditions. Notwithstanding anything in the Plan to the contrary: (i) Crosstex
may, if it shall determine it necessary or desirable for any reason, at the time of grant of any
Award or the issuance of any shares of Common Stock pursuant to any Award, require the recipient of
the Award or such shares of Common Stock, as a condition to the receipt thereof, to deliver to
Crosstex a written representation of present intention to acquire the Award or such shares of
Common Stock for his or her own account for investment and not for distribution; (ii) the
certificate for shares of Common Stock issued to a Participant may include any legend which the
Committee deems appropriate to reflect any restrictions on transfer, and (iii) all certificates for
shares of Common Stock delivered under the Plan shall be subject to such stop transfer orders and
other restrictions as the Committee may deem advisable under the rules, regulations and other
requirements of the SEC, any stock exchange upon which the Common Stock is then quoted, any
applicable federal or state securities law, and any applicable corporate law, and the Committee may
cause a legend or legends to be put on any such certificates to make appropriate reference to such
restrictions.

     11.4 Nonassignability. No Award granted under the Plan may be sold, transferred, pledged,
exchanged, hypothecated or otherwise disposed of, other than by will or pursuant to the applicable
laws of descent and distribution. Further, no such Award shall be subject to execution, attachment
or similar process. Any attempted sale, transfer, pledge, exchange, hypothecation or other
disposition of an Award not specifically permitted by the Plan or the Award Agreement shall be null
and void and without effect. All Awards granted to a Participant under the Plan shall be
exercisable during his or her lifetime only by such Participant or, in the event of the
Participant’s legal incapacity, by his or her guardian or legal representative. Notwithstanding
the foregoing, to the extent specifically provided by the Committee, an Award, including an Option,
may be transferred by a Participant without consideration to immediate family members or related
family trusts, limited partnerships or similar entities or on such terms and conditions as the
Committee may from time to time establish.

     11.5 Withholding Taxes. The Company shall be entitled to deduct from any payment made under the
Plan, regardless of the form of such payment, the amount of all applicable income and employment
taxes required by law to be withheld with respect to such payment, may require the Participant to
pay to the Company such withholding taxes prior to and as a condition of the making of any payment
or the issuance or delivery of any shares of Common Stock under the Plan, and shall be entitled to
deduct from any other compensation payable to the Participant any withholding obligations with
respect to Awards under the Plan. In accordance with any applicable administrative guidelines it
establishes, the Committee may allow a Participant to pay the amount of taxes required by law to be
withheld from or with respect to an Award by (i) withholding shares of Common Stock from any
payment of Common Stock due as a result of such Award, or (ii) permitting the Participant to
deliver to the Company previously acquired shares of Common Stock, in each case having a Fair
Market Value equal to the amount of such required withholding taxes. No payment shall be made and
no shares of Common Stock shall be issued pursuant to any Award unless and until the applicable tax
withholding obligations have been satisfied.

     11.6 No Fractional Shares. No fractional shares of Common Stock shall be issued or delivered
pursuant to the Plan or any Award granted hereunder, and except as otherwise provided herein, no
payment or other adjustment shall be made in respect of any such fractional share.

 Page 11 of 13 

 

     11.7 Notices. All notices required or permitted to be given or made under the Plan or any Award
Agreement shall be in writing and shall be deemed to have been duly given or made if (i) delivered
personally, (ii) transmitted by first class registered or certified United States mail, postage
prepaid, return receipt requested, (iii) sent by prepaid overnight courier service, or (iv) sent by
telecopy or facsimile transmission, answer back requested, to the person who is to receive it at
the address that such person has theretofore specified by written notice delivered in accordance
herewith. Such notices shall be effective (i) if delivered personally or sent by courier service,
upon actual receipt by the intended recipient, (ii) if mailed, upon the earlier of five days after
deposit in the mail or the date of delivery as shown by the return receipt therefor, or (iii) if
sent by telecopy or facsimile transmission, when the answer back is received. Crosstex or a
Participant may change, at any time and from time to time, by written notice to the other, the
address that it or such Participant had theretofore specified for receiving notices. Until such
address is changed in accordance herewith, notices hereunder or under an Award Agreement shall be
delivered or sent (i) to a Participant at his or her address as set forth in the records of the
Company or (ii) to Crosstex at the principal executive offices of Crosstex clearly marked
“Attention: LTIP Administrator.”

     11.8 Binding Effect. The obligations of Crosstex under the Plan shall be binding upon any
successor corporation or organization resulting from the merger, consolidation or other
reorganization of Crosstex, or upon any successor corporation or organization succeeding to all or
substantially all of the assets and business of Crosstex. The terms and conditions of the Plan
shall be binding upon each Participant and his or her heirs, legatees, distributees and legal
representatives.

     11.9 Severability. If any provision of the Plan or any Award Agreement is held to be illegal or
invalid for any reason, the illegality or invalidity shall not affect the remaining provisions of
the Plan or such agreement, as the case
may be, but such provision shall be fully severable and the Plan or such agreement, as the case may
be, shall be construed and enforced as if the illegal or invalid provision had never been included
herein or therein.

     11.10 No Restriction of Corporate Action. Nothing contained in the Plan shall be construed to
prevent Crosstex or any Affiliate from taking any corporate action (including any corporate action
to suspend, terminate, amend or modify the Plan) that is deemed by Crosstex or such Affiliate to be
appropriate or in its best interest, whether or not such action would have an adverse effect on the
Plan or any Awards made or to be made under the Plan. No Participant or other person shall have
any claim against Crosstex or any Affiliate as a result of such action.

     11.11 Governing Law. The Plan shall be governed by and construed in accordance with the internal
laws (and not the principles relating to conflicts of laws) of the State of Delaware except as
superseded by applicable federal law.

     11.12 No Right, Title or Interest in Company Assets. No Participant shall have any rights as a
stockholder of Crosstex as a result of participation in the Plan until the date of issuance of a
stock certificate in his or her name and, in the case of Restricted Stock, unless and until such
rights are granted to the Participant pursuant to the Plan. To the extent any person acquires a
right to receive payments from the Company under the Plan, such rights shall be no greater than the
rights of an unsecured general creditor of the Company, and such person shall not have any rights
in or against any specific assets of the Company. All of the Awards granted under the Plan shall
be unfunded.

     11.13 Risk of Participation. Nothing contained in the Plan shall be construed either as a
guarantee by Crosstex or its Affiliates, or their respective

 Page 12 of 13 

 

stockholders, directors, officers or
employees, of the value of any assets of the Plan or as an agreement by Crosstex or its Affiliates,
or their respective stockholders, directors, officers or employees, to indemnify anyone for any
losses, damages, costs or expenses resulting from participation in the Plan.

     11.14 No Guarantee of Tax Consequences. No person connected with the Plan in any capacity,
including, but not limited to, Crosstex and the Affiliates and their respective directors,
officers, agents and employees, makes any representation, commitment or guarantee that any tax
treatment, including, but not limited to, federal, state and local income, estate and gift tax
treatment, will be applicable with respect to any Awards or payments thereunder made to or for the
benefit of a Participant under the Plan or that such tax treatment will apply to or be available to
a Participant on account of participation in the Plan.

     11.15 Continued Employment or Service. Nothing contained in the Plan or in any Award Agreement
shall confer upon any Participant the right to continue in the employ or service of the Company, or
interfere in any way with the rights of the Company to terminate a Participant’s employment or
service at any time, with or without cause.

     11.16 Miscellaneous. Headings are given to the articles and sections of the Plan solely as a
convenience to facilitate reference. Such headings shall not be deemed in any way material or
relevant to the construction of the Plan or any provisions hereof. The use of the masculine gender
shall also include within its meaning the feminine. Wherever the context of the Plan dictates, the
use of the singular shall also include within its meaning the plural, and vice versa.

     IN WITNESS WHEREOF, this Plan has been executed as of this 6th day of September 2006.

	 	 	 	 	 
	 	CROSSTEX ENERGY, INC.

 	 
	 	By:  	/s/ William W. Davis
 	 
	 	 	William W. Davis 	 
	 	 	Senior Vice President and

Chief Financial Officer 	 
	 

 Page 13 of 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]